var title_f24_27_25008="Outcome of screening I";
var content_f24_27_25008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76245%7EPC%2F56330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76245%7EPC%2F56330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Chances of false-positive mammograms, need for biopsies, and development of breast cancer among 1000 women who undergo annual mammography for 10 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 368px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    All numbers are rounded. The number rates of false-positive mammograms and breast biopsies come from a single study in which, overall, the rate of false-positive mammograms was 6.5 percent, and the rate may be different in other settings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fletcher, SW, Elmore, JG, N Engl J Med 2003; 348:1672.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Chances of breast-cancer - related outcomes among 1000 women who undergo annual mammography for 10 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    All numbers are rounded. The numbers for the incidence of invasive breast cancer and ductal carcinoma in situ, as well as the number of women whose lives are saved by treatment (those surviving at least 20 years after the first diagnosis of breast cancer) regardless of screening, were calculated on the basis of data from the Surveillance, Epidemiology, and End Results program. The numbers of women whose lives are saved because of screening (those surviving at least 15 years after diagnosis) were calculated on the assumption of a reduction of 15 percent in mortality from breast cancer among women 40 to 49 years of age, 14 percent among women 50 to 59 years of age and 32 percent among women 60 to 69 years of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted and updated from: Fletcher, SW, Elmore, JG, N Engl J Med 2003; 348:1672.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25008=[""].join("\n");
var outline_f24_27_25008=null;
var title_f24_27_25009="Contents: Primary care endocrinology";
var content_f24_27_25009=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care endocrinology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care endocrinology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Calcium and magnesium disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13220\">",
"           Causes and treatment of hypermagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/41/15000\">",
"           Causes of hypomagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/26/5545\">",
"           Diagnosis and differential diagnosis of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20934\">",
"           Diagnostic approach to hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34005\">",
"           Diagnostic approach to hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/22/28007\">",
"           Etiology of hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/25/24984\">",
"           Etiology of hypocalcemia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/63/11254\">",
"           Evaluation and treatment of hypomagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/16/2310\">",
"           Hypercalcemia in granulomatous diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/48/41734\">",
"           Hypercalcemia of malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30361\">",
"           Pathogenesis and etiology of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18377\">",
"           Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/29/470\">",
"           Regulation of magnesium balance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23685\">",
"           Relation between total and ionized serum calcium concentration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16085\">",
"           Significance of hypomagnesemia in cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42580\">",
"           Signs and symptoms of magnesium depletion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32914\">",
"           Symptoms of hypermagnesemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/42/16041\">",
"           Treatment of hypercalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/37/44632\">",
"           Treatment of hypocalcemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes mellitus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/0/3078\">",
"           Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29641\">",
"           Blood glucose self-monitoring in management of adults with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/4/11332\">",
"           Case illustrating blood glucose monitoring in type 2 diabetes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/8/4232\">",
"           Cases illustrating problems with intensive insulin therapy for diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/7/12402\">",
"           Cases illustrating the effects of exercise in intensive insulin therapy for diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36023\">",
"           Classification and clinical features of diabetic retinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/33/14874\">",
"           Classification of diabetes mellitus and genetic diabetic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/55/4986\">",
"           Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/7/18551\">",
"           Clinical manifestations and diagnosis of diabetic polyneuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30970\">",
"           Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38758\">",
"           Diagnosis of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/35/22071\">",
"           Diagnostic dilemmas in hypoglycemia: Illustrative cases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/50/20265\">",
"           Effects of exercise in diabetes mellitus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16934\">",
"           Epidemiology and classification of diabetic neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38341\">",
"           Erectile dysfunction in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11993\">",
"           Estimation of blood glucose control in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/12/11464\">",
"           Evaluation of the diabetic foot",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/55/15225\">",
"           General principles of insulin therapy in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11817\">",
"           Glycemic control and vascular complications in type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7578\">",
"           Glycemic control and vascular complications in type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28569\">",
"           Heart failure in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/39/24184\">",
"           Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/35/43577\">",
"           Initial management of blood glucose in type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/20/24906\">",
"           Insulin therapy in adults with type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/24/30089\">",
"           Insulin therapy in type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26233\">",
"           Management of diabetes mellitus in hospitalized patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/28/37321\">",
"           Management of diabetic foot lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27641\">",
"           Management of hypoglycemia during treatment of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37866\">",
"           Medical management and follow-up of gestational diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/19/20794\">",
"           Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38312\">",
"           Metformin in the treatment of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/49/42777\">",
"           Microalbuminuria in type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/33/39449\">",
"           Microalbuminuria in type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/53/22358\">",
"           Musculoskeletal complications in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25641\">",
"           Nutritional considerations in type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/18/14634\">",
"           Nutritional considerations in type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/63/30714\">",
"           Overview of diabetic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36458\">",
"           Overview of medical care in adults with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/60/41928\">",
"           Pathogenesis and prevention of diabetic polyneuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23210\">",
"           Pathogenesis of type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/31/36346\">",
"           Pathogenesis of type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/21/32087\">",
"           Prediction of type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/27/36281\">",
"           Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42487\">",
"           Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/38/32362\">",
"           Prevention and treatment of diabetic retinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9210\">",
"           Screening and diagnosis of diabetes mellitus during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42501\">",
"           Screening for diabetic retinopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/46/35559\">",
"           Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/50/21290\">",
"           Thiazolidinediones in the treatment of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/48/15114\">",
"           Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/48/40714\">",
"           Treatment of diabetic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/43/12986\">",
"           Treatment of diabetic neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21210\">",
"           Treatment of hypertension in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/42/682\">",
"           Treatment of type 2 diabetes mellitus in the elderly patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Menopause and its treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/45/44761\">",
"           Clinical manifestations and diagnosis of menopause",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/34/40486\">",
"           Continuous postmenopausal hormone therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/38/41576\">",
"           Managing the side effects of tamoxifen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/53/25434\">",
"           Menopausal hot flashes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/11/11449\">",
"           Postmenopausal hormone therapy and the risk of breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16218\">",
"           Preparations for postmenopausal hormone therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40615\">",
"           Treatment of menopausal symptoms with hormone therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27384\">",
"           Causes and evaluation of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/9/6294\">",
"           Epidemiology and pathogenesis of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/47/760\">",
"           Management of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14810\">",
"           Overview of the treatment of endometriosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13034\">",
"           Physiology and clinical use of melatonin",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obesity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/9/8345\">",
"           Dietary therapy for obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33866\">",
"           Drug therapy of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3418\">",
"           Etiology and natural history of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30266\">",
"           Health hazards associated with obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13016\">",
"           Overview of therapy for obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21144\">",
"           Role of physical activity and exercise in obese adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/20/12615\">",
"           Screening for and clinical evaluation of obesity in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/55/11128\">",
"           Diagnosis and evaluation of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3929\">",
"           Pathogenesis of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42855\">",
"           Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/4/11333\">",
"           Pharmacology of bisphosphonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/36/17994\">",
"           Prevention and treatment of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44487\">",
"           Use of biochemical markers of bone turnover in osteoporosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pituitary and adrenal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/3/16435\">",
"           Basic principles in the laboratory evaluation of adrenocortical function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/55/26489\">",
"           Causes and pathophysiology of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/0/40969\">",
"           Causes of primary adrenal insufficiency (Addison's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/50/3880\">",
"           Causes of secondary and tertiary adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33800\">",
"           Clinical manifestations of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15878\">",
"           Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24520\">",
"           Craniopharyngioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31703\">",
"           Determinants of glucocorticoid dosing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/41/37528\">",
"           Dexamethasone suppression tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/46/44777\">",
"           Diagnosis of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22282\">",
"           Epidemiology and clinical manifestations of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31225\">",
"           Establishing the cause of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/25/21913\">",
"           Establishing the diagnosis of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9930\">",
"           Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22103\">",
"           Glucocorticoid withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25059\">",
"           Hypothalamic-pituitary axis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/43/12981\">",
"           Incidentally discovered sellar masses (pituitary incidentalomas)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23302\">",
"           Normal adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1016\">",
"           Overview of the treatment of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23208\">",
"           Pharmacologic use of glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21481\">",
"           Premature adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/8/18569\">",
"           The adrenal incidentaloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/47/42745\">",
"           Treatment of adrenal insufficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reproductive and sexual function",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36919\">",
"           Amenorrhea and infertility associated with exercise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22424\">",
"           Diagnosis and treatment of delayed puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/2/2089\">",
"           Etiology, diagnosis, and treatment of primary amenorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/56/34697\">",
"           Etiology, diagnosis, and treatment of secondary amenorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/49/32533\">",
"           Evaluation of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/56/17287\">",
"           Overview of infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/44/42696\">",
"           Overview of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/57/42904\">",
"           The sexual history and approach to the patient with sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2630\">",
"           Transsexualism: Epidemiology, pathophysiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/36/30282\">",
"           Treatment of male sexual dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/25/8602\">",
"           Treatment of transsexualism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21050\">",
"           Use of androgens and other hormones to enhance athletic performance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3046\">",
"           Cardiovascular effects of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14503\">",
"           Clinical manifestations of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26744\">",
"           Diagnosis of and screening for hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/57/26520\">",
"           Diagnosis of hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28506\">",
"           Diagnostic approach to and treatment of thyroid nodules",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4103\">",
"           Disorders that cause hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/47/42744\">",
"           Disorders that cause hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3608\">",
"           Laboratory assessment of thyroid function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/60/14279\">",
"           Overview of the clinical manifestations of hyperthyroidism in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/17/44313\">",
"           Overview of the management of differentiated thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/248\">",
"           Postpartum thyroiditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23913\">",
"           Subclinical hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/48/3850\">",
"           Subclinical hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/25/12696\">",
"           Thionamides in the treatment of Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44663\">",
"           Thyroid function in nonthyroidal illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/0/22535\">",
"           Thyroid hormone suppressive therapy for thyroid nodules and benign goiter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33320\">",
"           Thyroid hormone synthesis and physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21143\">",
"           Treatment of Graves' hyperthyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/26/35239\">",
"           Treatment of Graves' orbitopathy (ophthalmopathy)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/53/43865\">",
"           Treatment of hypothyroidism",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2EC024B9AE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f24_27_25009=[""].join("\n");
var outline_f24_27_25009=null;
var title_f24_27_25010="AML FAB M5B maturation";
var content_f24_27_25010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute monocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow smear from a patient with acute monocytic leukemia with maturation (FAB M5B). This field shows a range of maturation of monocytic cells. (Wright-Giemsa stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25010=[""].join("\n");
var outline_f24_27_25010=null;
var title_f24_27_25011="Auxiliary service interaction";
var content_f24_27_25011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The interactive association between the auxiliary services",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Chantal Lau, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25011=[""].join("\n");
var outline_f24_27_25011=null;
var title_f24_27_25012="Polymyxin B: Pediatric drug information";
var content_f24_27_25012=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polymyxin B: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"    see \"Polymyxin B: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/31/15860?source=see_link\">",
"    see \"Polymyxin B: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Urinary Irrigation",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"      see \"Polymyxin B: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Avoid parenteral use when possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &lt;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 25,000-40,000 units/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15,000-45,000 units/kg/day by continuous I.V. infusion or divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intrathecal: 20,000 units once daily for 3-4 days or 25,000 units once every other day; continue 25,000 units once every other day for at least 2 weeks after cultures of the CSF are negative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 25,000-30,000 units/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15,000-25,000 units/kg/day divided every 12 hours or by continuous infusion; total daily dose should not exceed 2,000,000 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bladder irrigation: Continuous irrigation of the urinary bladder for up to 10 days using 20 mg (equal to 200,000 units) added to 1 L of NS; usually no more than 1 L of irrigant is used per day unless urine flow rate is high; administration rate is adjusted to patient's urine output",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical irrigation or topical solution: 0.1% to 0.3% solution used to irrigate infected wounds; should not exceed 2 million units/day in adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gut sterilization: Oral: 100,000-200,000 units/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: 2-2.5 mg/kg/day divided every 6 hours; final concentration for administration should not exceed 10 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intrathecal: 50,000 units once daily for 3-4 days, then reduce to once every other day for at least 2 weeks after cultures of the CSF are negative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5-20 mL/minute: Administer 50% of usual daily dose divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;5 mL/minute: Administer 15% of the usual daily dose divided every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding [micronized]: 50 million units, 100 million units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral (avoid parenteral use whenever possible):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Not recommended for routine use in infants and children because of the severe pain which occurs with I.M. injection; administer I.M. injections deep into the upper outer quadrant of the gluteal muscles at a final concentration of 250,000 units/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Infuse drug slowly over 60-90 minutes or by continuous infusion at a concentration of 1000-1667 units/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal: Reconstitute vial with 10 mL NS without preservatives to provide a final concentration of 50,000 units/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F211333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Penicillin G sodium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cloxacillin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; incompatible with calcium, magnesium, cephalothin, chloramphenicol, heparin, penicillins; inactivated by acidic or alkaline solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topically for wound irrigation and bladder irrigation against",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ; used occasionally for gut decontamination. Parenteral use of polymyxin B has mainly been replaced by less toxic antibiotics. Reserved for life-threatening infections caused by organisms resistant to the preferred drugs; used as inhalation therapy for gram-negative respiratory infections resistant to preferred drugs; used intrathecally for meningeal infections due to susceptible organisms which are resistant to less toxic antibiotics",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F211332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Facial flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Neurotoxicity (irritability, drowsiness, ataxia, perioral paresthesia, numbness of the extremities, and blurred vision); dizziness, drug fever, meningeal irritation with intrathecal administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticarial rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia, hyponatremia, hypokalemia, hypochloremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuromuscular blockade, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to polymyxin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with myasthenia gravis, patients receiving neuromuscular blocking agents or anesthetics, and in patients with impaired renal function; modify dosage in patients with renal impairment;",
"     <b>",
"      I.M. use is not recommended in infants and children due to severe pain at injection site",
"     </b>",
"     . Safety in pregnant women has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause nephrotoxicity; renal function should be evaluated prior to initiation; patients with renal damage and nitrogen retention should receive reduced dosage",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; polymyxin B-induced nephrotoxicity may be manifested by albuminuria, cellular casts, and azotemia; discontinue therapy with decreasing urinary output and increasing BUN. May cause neurotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; neurotoxic reactions may be manifested by irritability, weakness, drowsiness, ataxia, perioral paresthesia, numbness of the extremities, and blurring of vision. These reactions are usually associated with high serum levels found in patients with impaired renal function or nephrotoxicity. Avoid concurrent or sequential use of other nephrotoxic and neurotoxic drugs, particularly bacitracin, kanamycin, streptomycin, paromomycin, colistin, tobramycin, neomycin, gentamicin, and amikacin",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . The drug's neurotoxicity can result in respiratory paralysis from neuromuscular blockade, especially when the drug is given soon after anesthesia or muscle relaxants. Polymyxin B sulfate is toxic when given parenterally;",
"     <b>",
"      avoid parenteral use whenever possible",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     : Safety in pregnant women has not been established. A teratogenic potential has not been identified for polymyxin B, but very limited data is available. Based on the relative toxicity compared to other antibiotics, systemic use in pregnancy cannot be recommended. Due to limited absorption through the maternal skin, limited fetal exposure would be expected after topical polymyxin use.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     WBC, serum electrolytes, renal function tests, serum drug concentration, urine output",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1049462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentration &gt;5 mcg/mL are toxic in adults",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to phospholipids, alters permeability and damages the bacterial cytoplasmic membrane permitting leakage of intracellular constituents",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from the peritoneum; minimal absorption (&lt;10%) from the GI tract (except in neonates), from mucous membranes or intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed to body tissues in the liver, kidneys, heart, muscle; does not penetrate into CSF or synovial fluid; does not cross the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 4.5-6 hours, increased with reduced renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily as unchanged drug (&gt;60%) in urine via glomerular filtration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 mg = 10,000 units; neuromuscular blockade may be reversed with calcium chloride",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12716 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25012=[""].join("\n");
var outline_f24_27_25012=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709216\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049460\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049454\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211287\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211272\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049464\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211333\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049457\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049463\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977966\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211332\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049467\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049453\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049452\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299903\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211281\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211283\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211295\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049459\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049462\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049451\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049466\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049468\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12716\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12716|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=related_link\">",
"      Polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/31/15860?source=related_link\">",
"      Polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_27_25013="Hilar adenopathy PA";
var content_f24_27_25013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1063px;\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 245px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD1AdkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiirtlZNcLuO4L7UAUqK7TRfCMF+yCaWePd3BH+Fd5ofwj0i+ukhmn1QbuAUkjH4/cNAHh9FfYVh+zD4QltVlutS8QozfwiaEfj/qjUKfszeEZXmMep6+scZK8zQnntz5VAHyHRX2LZ/sweDbm080al4iR8Hgzw8/+Qq4vxP8CvDWkllhvtZZ/wCHfLEcj1/1YoA+bqK9K8Q/D+y00/uLi5kBGRuZf/ia4jUNM+zfcLEe9AGZRSng0lABRRRQAUUUUAFFFFABRRXpXwc+Hdv48TWWuZrmIWBhx5LKM+Z5nXIP9ygDzWivpEfAHSBw15qoP+/H/wDEUv8AwoPQgPmvdX/7+R//ABugD5tor6Wn/Z90eBFd7nWQh6HzI/8A4ikh+Afh9Y2luLzWPK6DbNED+sdAHzVRX0XD8E/Ctw5EOoawvPCvLEDj/v3V9P2fvD2AXvdZ57CWLP8A6LoA+ZaK+g9Z+Cfh6yRvs+p6jLKP+WZkj4+p2V5hr3g/+zJWHkXewDIO8Nn8lFAHF0VOkQMhDq4GfpVlba1ZlBd1zwckcfpQBn0V0+k6Jp893tvJpjD0zEwBB/FTXpmkfCfw3qEUcgvtU2sM5Ekf/wARQB4ZRX0DJ8GvDRQ+VfasWBxgyx//ABuq0Hwf8Pvc+VJeaoBnHEsef/QKAPB6K+j7z4IeFLSz8+XUNZOBk4liH/tOvMNR8G6dDeTRwyXkcaE482RSf0UCgDz+iuhvNDQSbLNLl8Dq2MH6cVNpfhC9v7gRgogJ9dx/QUAcxRXuGlfCDR5Y1N9f6gGxz5ZQfzU1t2/wV8KMw8y+1rafSaL/AON0AfOlFfUlp8BfA92NsGqa682PuC4h5P18qop/2ffDKMNl/rRUnABmiyD6H93QB8wUV9P6r+zpox0W7k0W81WTVBCxtop54gjS9lY+WOD06iua0j9mXxjfW4a6FhYSZwRPe7uPUBEYH86APBaK+pdN/ZMnZ86n4qjRMdLe1LHP1LCulsf2UfCyRKL7Xdbmk7tCYoh+RRv50AfGtFfah/ZV8EAf8hTxL/4EQf8Axmvl/wCMfhWy8E/EjWPD+lTXE1nZ+Tse4ZWkO+FHOSoA6sR06UAcXRRRQAUUUUAFFFFABRRSgE9AaAEoqaO2kfouB71ettJmnOI45JGxkhFJwO5oAy6cEY9BW9FoM7YIQ4rQj0SSIqGj3HpgDNAHLx27N2r0TwP4ZutUt49iFbcHLS4/Qe9bXhP4a3d/sur+BorYnKxE7Wk/wHvXsUVvpPhbSIW1O6t4HC4S2iG5gPp2FAGF4e0SKwuf3MQQldnz85rt7C0hWXNzbbSBwVJUn+hrjl8aaPcX6RWoLd8MpUn6HOK7bQdTtr04iaRH6iKXlW/3W70Aei6KHuNMQxuVAAUM3aufbR9SvtafZqSxBGLKA3GT2x3/ABro7GeJbRBEI1UL82ODXE6p4pt7DUzmOV3D/KUHA57/AJUAd1pq3Ntpp890kZCeUNcN4jSK7k3zebcuCeN3A/rXX6BfxXWlGV1VkYlvx/pXN67cFJJFR3jjA+5EMcepPagDy7xVpUN1GA8CxuGyNow2PQ+1eXeNPCckERuLaNzEBlgRyv19vevVdW1/QtL1fZqruZWUHyoWLtz3Y4wPpV631Dw1rMLC1nMMm3/V3Enln8M4zQB8l3diyueMVSeF06ivpvXPhlpeqxtdaVJk8l0t5VkA9wP6VwWofDi8jLfZsXSjqoXDr7le/wCGaAPHtp9KbXo8vg9tuQh4HpUOu/D7UdNginlhSSKVA6NE2eDQB59RWzPoNyoyiN9CMVmzWk0JIeNhj2oAgopT70lABX1P+w5Gsg8bBwCuLIEEZz/r6+WK+p/2HWZR412LuJ+xD/0ooA+mZtFtnJKjC/3e1Qf2JGjZijTI6FuSK2Y23xq21lyM4bqKiuJGQHb0oAzLu2ht4m85RLuGCG+7XHX0ZlicO5c42qcAAfQDgV1GoICuRnB96yRZmVztB6YJ9KAOLg03bLv2blB+UY6n39qxPFvi/wDseL7LBL5krffxyR7A9q2vGfiCGzgaz08KzDh5Cflz6e/1rwHxte3U8wdZZCpyp2DA/SgDrh4jt7p8y7oWPeRsj86ZdMJl+aNJEweh3A14hcXMyMcb855Jp8GsXEBzE0iHvzigDstc0eymZ5vsSbu+wlTXOSaHprzj/XoTyQGzUQ8RXDEC4h8xT3Hyk/lxVafUV+0ArLND3Cycj8//AK1AHWaP4bt1lbZLOUJzzgV6n4X06WzCpvLxFdyAnGDXk2j6tdpLGu5CvQg9PrXrHhnWo76VIgrAx4AxzkUAdG8FxbM0nk+YPQHFS2FpLPOkpjWPd2J5GPetdEzHvKsEU5NOsoWiywUsRnrQBR1y1+05TzBtReg6Z9a868R2GnWdvul3GZ25Jbk16BrV48MskKJt3cZ7jNeI+Mje3OrSIA20DAOeMUANvdQ0pCFWPzG+7kjOPxrR0G+UzDy4lCDjrx+lcP5EMLBZZlnlBAKRZAX6k/0qSfW5E/cxKI40ONqnFAHq/wDwlEFkm2WVTIvG1AM/jmsjUfHdzwqSIiHsAD+deYtqmHJHlqMnIOOarrf7p8mWLOenFAHr2i+N38+IbFLAjmM7T/hXvvhHU7bW4QszBbgjABGGP+Jr5X8Jw/aLhGeON1TBJXB/lXtvhq4WJI8EoRyDnvQB6+lr5bY9O/b61s2UzJEqn5mPQ1keHb/+0rTy5yPtI53f3h6/41q20RQbWLMQx+9jj24oA0Y23KCetRr5q3LAndEwyvH3SMDH49fzp2VGwN3OB9etSUAFfAH7Uf8AyXbxN/27f+ksVff4GM4r4A/aj/5Lt4m/7df/AElioA8qooooAKKK7n4I6Va638UNE0+/gt7i1lMpkiuFLIwWF25A+nHvigDiFUuwVQST2Fa2l6DcXzgNJHCp6ljyPwr7Hn+GuhxGSW009IAxKhVA4GcjtVO38I6dplwGGjxvj+JsH+YoA8T8MfCOw1CNJLq/uXB6iFR/9evQ9J+Bvh/YVkS9LcfMZcH+Ves6ZLMAsdnFb2S4xhbVWP5nNdTZDUowomuhID0TyAC35AUAeEP8CbIyAaXdsXzxHOo5/EV2Wg/DGPwrpskrwpJdupLyLyFGOg9q9NGrW8MrKIQ8uSHeIg7fz6/hWlZSRXIZo5CwPUEYP60AfNmnfDsTKZpojHBuO0hclvZRTdai8O+DmAvGSKcruMSjfO49+yD8q938aX9rp9q0USEXbpgNCPmjX1r5s1/wPaapf3Fz/acSyynJN4+5j+IP9KAOY8QfFy6/e/2bbpCqjCBzuPtwMCvObzxhrd6JGutSuWaQksA2BXY6t8P2jLCG406UAH7lymT+eK4S+0K8tp2jaFCQf4ZFI/Q0ANh17UIZQ8F7Mp9Ww2PzzXs/wp8dpdTxadrBjVpDhZUyqsfcdj7j8q8ZtNCuZpMGEgdM71A/PNegeGfAF4kcF1KrqrOAvzcjPQ0AfWnh29jSyPmyJMgwFZ+W56ZPese+tbe9vbmRLC3cAFunBwf0rP8ABum3sGkxQTSrNOOWLtzx0/SrulRatb3txB9jilR2yJd+AOvPv16UAdp4fiifRBsSKLPGVHTjtXjHx58eW3h+AabYxtc3TA7huIX/AIEep+lez29vLYeHGQyRpJggMAeDXgXxD8GrdCWa8eaTDF2OeWbtz6UAfOes+IdR1C4aS4n2FuqxDaP8f1rFLyFxJliw53Guh1zSpLK5kLxvEhYjhc5+nrWSlq9xMqJDMxP975aANrRNR1CzmjurO5MEp6lXxn6gV7d4B8YTzslt4hmglAIMU5JVwD74rzTw9pixNGZ4rKJehLM0h/IcV3cFzp1msZNpaXfZSysgI/BqAPYLrwxa63bCeFUct0uYwDz6OB1+vX61s6J4LE+lnT9YttkMeVWQkfL6EeorlPh/42stLaLFolnE5Ak8tspgnvu5H5mvatP1Ow1m1aewnS4RTtyjAn/6340AeYXHwe0hT/pDzzqxyBEoUfnWBrnwc0CaJh9hnixwGSQk17VJqqwMkYhIz2Y81bMsk8W+2ZcHpkUAfHPiz4J2ttG0llNfdMgeSHH6YNeUav4J1CwlYIBMB2wVb8jX6AaxIzJtuLRZD3ZRjn3rkZvC0eqTbntGC56sBxQB8A19VfsMf8zt/wBuP/txXyrX1V+wx/zO3/bj/wC3FAH1VUM/3TUpOO1Qz/WgDG1DdHCxjQyNnAUEAn8+KxfFN0dO0jy4WCNJkF++O+PrXSqnmzDIwgP5n0ryr4n65vkkSzYERfLv7fgKAPO/EN6luzMxRc/xSN/SvONe1a2kVlaV5R0OzpV3xCLm4ld5Dk9cu3+TXCalFsYlpi4HVVHQUAZWrXMRfKBivvisl5Q3RcCrN4I0JA3t9TVFsZ4GKALEU4UjfnFWUulkkXfIAO+R0FZtKKAPQ/D4EiKsc8bIxJOV5HFeneCLNLaRZEcAZw2cnJr54s7maCQGItx6V7T8N9YlvbdI5FzICBn3oA94hjlW3Qo4JPbPar1nA7QEyyElm5xVe2UtBDjAwAcVqWkTPFwQD1zQBha5axN5wYHKr1PevA/Gt/Hb3EyvKflJxtwCfxr3vxcJoxNjPzDmvl34i21yNblBYrGV3Dd6ZoA5O91aV5AYQIwp4x1rOubuWaQu0jEty3PeluECA5DE561FFC8jFVHIGeTigCMknrU9qG34Ck59qhA5xkVpWbxKU+YAfxHp0oA67w5IsRUIcFec+tel+H9dmUoqy74x/fOa8w0e4WVvldSnTk8n6V3WiRxnYzRhM9CvH/1qAPefAmvIbuFejFh8hPX6f4V6y+1CGJG3GcnjpXzf4bikjmWRTvRcHI4I/wA+1e++G77+1NIjZz++X5WPuOh/GgDXeXbEHXBz90dck9KmrLuJGjtGZBgxHJOPbqPzrTU5UH1FABk78bTjGd3GPpXwD+1H/wAl28Tf9uv/AKSxV9/n2r4A/aj/AOS7eJv+3X/0lioA8qooooAK734FadJq3xV0OyhOJJDMQd23pBI3X8K4KvVf2XP+S6+Gf+3n/wBJZaAPsnw/pup6W6w38b3NscDJbcV+h9K6x9PtnXDRKfwq1RQBTttNtrd9yRgt6ml1SIzWbopIJ447+1W6ZKu5cUAcfFpUjXyeUuNpznt+PtVDx54wi8JWX2TT0Wa/cEkt0T346n2rs9Rf7FYyPGQrnjcRnFfOvxJ1+x0i+JurhIp3XcP+WkxyfTt+lAHm3j3xv4tm1BZJLy4MEif6qUfu8gnoPyrmLPxm0bYvLCMA8M8Mu0n8D/jTPFfiW2vldIIJX+bPmTtgg+wH+NcNcXbM/CRr7CgD0+bW9J1BET7ekDY4FyjD36gEVgajoU98ZGspbK5kXLBYZwxYewrjDdyYA+XA6cVIl4ygtsQnp3oA07fTdRt7lQsEsco6ADB/Cu20zxHrWi6VI/mOQzIAkykgYI9elcToeuNZXKeejz2xPzQtIcfh6fhXsWgzWPiK2tftDRJEzFkh3ckA459s5oA9g+FHiE+I7WS4Nvsm2gMA3Abjp7V6BpdhsluF2YEhxx2xzWF8MtPtLJDBbR7AVDMqqAB+HY12senRLdtLGzITneAcbvrQBX1I+TpRygKoQxB7DvXz5+0ANZvEjjtd4hdt2yPgEdq+lrq3ie1dSoK9MdjXjXxq1ez0JLc3VqZPkwCrAH9aAPkkaPf3FwEnLqx5xguwH0rrLTwnBptqk15IxmKb282Ty1C+w6msPxB461S4uWWwdLGBSdiW424Huw5Y+5rkr68nu3DzzSyHH8TE4oA9Wk1jw3psIizDNKoH+rBYdO5JxWHqnjmORtum2VnAoOFeQBj9cdK84bJpACe2aAO1sLq61a/ja5D3O07ztc4AHsDgV7r8NfEN1o00TWM7dg0MnRl9M/418wWoeJ8/MjDnI4xXb+FvFuo2d3DG8gvLYEbkn6kegbqP1+lAH3xAsWq2dtexoVYqNynqPb8K07eJYY8KMetcl8LtbtdY8OwtbO2VQExv95AR+o9xXZUAMkiST76g0qIqDCqAKdRQB+VdfVX7DJwPG5Az/wAeXH/gRXyrX1V+wx18ben+hf8AtegD6ozxnB9cVBdEbMng4zzU7cYyTxVC7ky2ByM0AUfEFy1no8hjbEjDaD6ZHJrxTX9ixPIzgLzukk6D2r1rx/OtrpBMnQc7R1dvSvnPxLfz3MrOWynIx0UD2oA5LxRqFvE7mGN5v9tjtA/rXnOsahdzZAMaDO792oFdxqkcbE/M0meML0+nNcbqlogLGOIkDsSeKAOYld2YlmJzzzUdXLiNUYZRQCOMHioDESMp8w7gdRQBFTlOCDgHFKqMwYgHC9fanRxFgcEZBxigCexkjRvnyMkV7H8LvIDpIQQ4PBU9a8YaB42UfxV6h8I0uH1BIwf3fVsUAfUdnGrLDtbaQo4Iz2rodKs1Z+p9sDpXJaS7s8W5jkAKfpXd6cqZJBOAPSgDmvE0Ef7wOmAFPXrXzz8V7NJbN5kjHmx52nHP0+lfSHi23eRMrjkEHHpXiPjnTWNhckkAbCeaAPmSed5nLOevYVFVqa2YPIcjAJ6Cllt0VYthyWxuyelAFOnLyw61NKqeYAqgDGMdzVqOJAiqoBfucZxQBZ03mVSwGAMADiu58NXtwmPKn4z9zr+lclplhvZQseCxwcHGPzrrtGtBCR5Uis56lhj8jQB674Z1aLEaPtjbj5lPyk/0r2rwDLlZgvGQCV9/WvmbT7iXzEDptXP3h0/A17z8I9QzKtvK2cjCN+HSgD0mZVk82FiQJFKnHoRT9KLLZxwSnMsCiN/fA6/Q9ahuwUnJGcHmnxZkZXU7Zl4z/eHoaAL9fAH7Uf8AyXbxN/26/wDpLFX37nIGVPPb0r4C/aj/AOS7eJv+3X/0lioA8qooooAK9V/Zc4+Ovhn/ALev/SWWvKq9V/Zc/wCS7eGf+3r/ANJZaAPv+iiigAooooA4j4m6ndW+mC3044lc4ZlGWA9B6fWvk/x5oss+qTy3Vx8+PuJ8znHqen86+q/Gk1vaWm68l+ZupUfPL64HYfpXyb8QPE1+2oSrYxpZQsx2Og3SuPd+x9lAoA4S+svIUmSArg/embB9uOKxLkqG2ho/+AgVPdxT3EjSOsskpPLPkk/iaoMjA8jFACEj1pVI9qbtPpSYPpQBZVFIPykH2Ndd4Hsru8uhFazFWAyAeK4pSykFSQa6nwRr76Vq8EsjDYHBJzgigD7N+DEF+kP+nys5jiCqSeTn+denxpgkg845rmPh1dQ3ejW0kZXLRhmAxkHFdcAOeKAIbhN1u3qea+bP2jtHurvRIZSCrxzeYx7hSMV9MNkK3P0ryP4ybL3TLi1wSXiK8DJz6e1AHxLNGLdj56b277qobkaQBnAHTgZ/lUurpJFfTQyFjsYgZNUlyDkUAK2ATzz9KniaFVG4kHPJAqsQTk4NKsUjkBUYn2FAGxYzQlyFm2A8ZYYBrtNA0WC7CSPGjpkfvYT938uPzFeeW8ZD/OPbGK6Xw09zFeRyWdzJDIDnKHAA9x3oA+vPg5YyadDbyq4mgVfL3gYIB9RXsteNfCHxJFLZ28F4qxTn5VkXhXPuOxP5fSvZR0oAKCM0UUAflXX1V+wzwPG3/bj/AO3FfKtfVH7DjBR42z3+xD/0ooA+pLl8RrkEE9qrRjfOmQeDmo7m5RpxHuG8jOKmtPmkPqQaAOH+Jj75oo5DmNI87fUk9fpXg/i2SC0Je8fYp+4iD5vwHYfWvZfjDe/YZvMGGkZNqgj7uO5/pXzh4iuDdPJ5jOd55fqTQBzWqawUZvskQ+rncfxrmr3VbqUk+YI8DoABVq/SUOyIu9s4ygzkVj3FrcnJbCqOxPI+ooArS3U0g+eQkZzUfnS7SBI2DyeaJI8MRuyR+FNCkEEUACzODncc9881etrxGcCSCPd03KMH8u9Vo4POYAMN5PIxxW7pvhya4g+0KvyZGVJ5A9aALCxQMFLH5+/y9K9b+FsNrBDJcsMnI+deOleRjS7y3uMREljnPPfvXp3gKC+bZC3CHk9uaAPojQoFMEbKRluMnoRXXW8RQAbs9OneuX8J20hjgWTJAUD8q7NochmXPFAGRrAjKg4Gcd+xryDxqYp7O5ic8MhXI+leta5HJ5fBxn1ryXxTaTGCVmVjwcEc5oA+U7u0uluXhaLlWIyx60t/bukSvJKWfjKooAFeneINAaSWO4WBskhWwK53VdDdcyRRuUBxhhjFAHCXaiGT5XDbhkE9QKS2Y9SxODyK2Z9MlNy/nRllKlgxI/Gs7yTjaFYAHJ4oAv2eoTAjB4xg9K6TR9WgYlJF245LLzXDiZA20IcDitO0nI2kvlRgDC4FAHsegSRXCI8Db4s4PP6Yr1/wWgtZreSPgo6uV/nivnXwtdSQzJNA/wAq8gqe/uK908B6wt7NEj7UuODgcBv/AK/tQB7xfgeWsigkkgHH6VBazgTqM5zT7mUG0jYfdYAj8q4rU9TnstYheB/lAG9TyDQB6OGBGQeK+AP2ojn46+Jz72w/8loq+5dO1SO7tY5Fbl22kDnB718M/tPtv+OXiVgCM/ZuD/17RUAeWUUUUAFeq/suf8l28M/9vX/pLLXlVeq/suf8l28M/wDb1/6Sy0Aff9FFFABUdzL5NvJJjO1ScetSUjjcpBGaAPDPGYnlmuby+Zvn52D7xHb6D2ryfWrAfZZGRLe1gb/lu4CnPYhj/SvUvjTry6Isq6eiTXLtzNIu5Iz3wP4iPfivmDW7+7vZ3nubqactywlbdj6DoKAINdMEUx336XHo0ZLA/wCFc7cSQuCQW3Z54xUt2VO4jB7cGqLq390/lQAp2YyGOfpUkIjZDl8PnoV6j61CEYjhTx7UKGzkD9KAL9vAZlYhQwB+tdn8OPB0uu6/bNLEEtc+YwPcDnAFcRaDYwZiVJ5UivTvhV4hfS9T3XErlFQgdGHPtQB9dfDzTJdNt1SRT8wBVhyMY713NcD8NvEMOugPbhtoTac8Yx7V31ABXKeKPD0F9GS4ABB6811dYHiq88m12pkHHXFAHxH8afCqaH4xlEECrb3CiRSBwG5yP61wMkMcVo+4ospPTPUf0r3n4r6Nc+Ib9zk5X7pY8AivKRoUcdlP9rDpIRhAo4z9fzoA46Vk2qAQfpT4pUVQoOCepA/SpL21FtEhZW8wnHPT61TRd2eDx3oA6jQ7QXEiqJUjDZ5YjOPoetd5oOj2saqJIPKk7zIOv1HTFeTWm/eCGwfc9a7Pw7r+o2PyJMJIuD5MoyrDv7igD3DwRaXEcwVGWa3B3ArwR7lfT86+ldNLHT7fzDl9gyfwrwH4QalaavqNsqRfY7s4LRH7rD/Zb+hr6FiQIgAAHsOKAHUUUUAflXX0J+yhqkmn2/i6KE7Wm+yZfuAPO/xr57r2T9nWQpNrmCeTb/8AtSgD6TstReK8imkdiu7DZOePWvSdOmDMTkHgAfjXjlrNvfYf8mvRPCd2ZIVib7ysoH05oA8++KbPqV/eqgJaNyi5GBxx1PavCdYtorVmDkyPnqchV/DvXuPji4MWo3UeckSMTn1zya8J8YahFG7G3AmJJyx+7n2HegDm9QJwcZ9mXgCuauXEJJaRCTzwc06/vJ5nYOx9MDtWVMDyGDDPPNAEk06sOCDnrkUxboqoGAfwAqArxlTmnRpvJBOBigC1BdIrgmMjHIIb/wCtXXaBdo9wWBmQOuTzkfXiuQis5G4CsxHoDXp3gTRJktImuYAUdyFyOVGO9AGpGlvJAkk7IXyAPf1Neh+DbKANE68ZIP1rgnsmeVEiUbU6bzXpngO1mlVV2BcHA7UAe06DAI4I8FQe5x1roIYztIO0kjGMVi6SNwjUs3AwMHg+1b0abTxmgDM1ezV03A4HevNNfSNIZgcED36V61fRmSFgPTp615T4s09mSYKCntQB59qP2Nw8cjRjcOAxxyK4nWSt82+KSJUTC4UEBR0445+tdjqeks25SOa4a0gmS5lilfbHGSNgHJ9//r0Acd4ohhgTbBKrs2VwOo9SfSuVilWFyEZ8kYJU44rtPFTWypIqwZVnwCep/H1rh5DCzGNkZJc4B9PagCwohc/6vcq8kMetWbOBXl2+V8vcelYyFlm2kkFe1athqEQwJVdVBx70Adbp0QjjHknBXkqTgn8a73wVdSLfRMxIkDBvcYrzzTLmCZlSGZM5GA2ATXoHh3auC42nPB7igD6gs74X3hq1nBG4ruP1HDCuF1iTMzyMxJOQPar/AIIu2/4RoRSE/JMR+DL/APWrD1R8qwJPFAFjQdbbTdQiWQloJeCPQ9iK+YP2k5RP8afEMqkEMLYgj/r2ir3S6uNyhh+HtXzl8Yrk3nxF1WdvvMsGfqIIx/SgDi6KKKACvVf2XP8Aku3hn/t6/wDSWWvKq9V/Zc/5Lt4Z/wC3r/0lloA+/wCiiigAqlrM7W+nyun3sY47VdqK6hW4geOQZUjpQB85fErT5tWzHEAEAJ81+EU+pNeHavoVvb+YZS3yHBLHCk/7IHJr6T+Jk8VlC5u5ktbRDgMcYB9AO/0FfNfjrxFBey4s03bePMkGCfwHSgDlriOGJi0KlRnggcVmTlWbh8nvk4qO7uppj+9djjt0AqqfWgCxwMZccds1u+GLbT7vUIV1G6jggLbXDE8+nOOlc2K2PDgjbUoVuFLQE5YA8mgD2iLwVoc9qohhjnCptEkUmcH+8cHk1c8PfD2K3nyg+RjuRnXlh7/jVzT9PC6VFfwyK68J+6OG2noataNq9wuqiPzZGWPChQdw/KgD3b4Y6F/Y+ny7oUjZ9vK9+K7Wsfwu/m6VG4BUEDg9q2KACqGqWEd5HtkAx61fqC8LCElBzQB5zqHhO1Zp0lBPzblBOa4nV/Cdm8U6fZRIkY3lnBIGe1dvq2r3qSy7Nh2k8MvSuL8Sa5eX10lvDcvDFLgNGG2hXxgmgDy3xL4NsM20TwK2ZPvYbOD05HYV5Rd29pJqDxKghjVjysmeley+LL3UYLW4itjdI8cZAO/duHckn8sV4NqV1ObuRjGqHPI24oAf5LM5EbEgHABHOPwrX022mhZJDC0iZ5C8n8utY1rqrIw35UgfKV9a6/wfdI14JPPVT6dz+FAHsHwtXyHhkD5nkYHBOCB7j2r6b0C8a8sFaQkuvG71FfPPhZkvZrdZUAl/vIMMR719AeFoGg01Qxzuxg4xkfSgDYooFFAH5V1678AX2PrhH/TD/wBqV5FXqvwLfbJrIPfyf/alAHvemygsSMZ6Gu88GTEXreipu/HIx/OvNNOYiT5e/evQfBufNyf4nRSfbJoA8t+N2oPBqk1vGSBJ88pHf2rxfUJlkjPmNkH0Ar2b4nWkmo6pdMg5WRjnHbNeV3tjHa5I+frkkdP8KAOHu7S43HZGSvZzwaptZL3kYuBz2H510epkOrKWIU9COlc1cyLE2UIds8GgCWyhCtjylkbsB6VoJb4GBAqtnlt44rEluZFClHKlxlsUsLuXGXJJPBHOaAPSfBOnQ3c+LiSMog3ZCliPT2NeiW15a2MRWeY+WDkHZwfSuC8FF49MkDqRJIeWDc4rfiAU+XLC0qScjeTx70AdFYvFqVyJ08gR5GeleneGLdY5UaEoFyMAV5Fp88NnElt5SrJI3zFGzz2r2HwTaNPHBkuo4JBoA9H0wMSpVhx221soD3IP4VUslAIKjAA6VdoARhkYrlvEFipjkLDI+nvXVVzviHJSQAmgDhNQ02KRGGwflXmetaGEvZJSroMclR0Fer3CydNzY9jXN67Aws5XVjuQ9xnI9aAPnzxPp223HklnjRyy8d/cVxd9avclZQRvAAO4Y4r1TxHCq3G5lYI/OV6Z9K88u5Yo5cxlgqt0J6j+tAHPXkUkcjgnBGBxyarhmdhG2Qf73rW/eLb3SGaJSrk/d6c/WqqQx/KkqHn8x+NADbBGMqpg9evavRPDGtmBo4LsloQdokzkp/iK5Kz0yRUIQhlHqMEVesgTJ911IPKsOlAH1d4CHm+GphnJEgcH1GKwtVyC/oSatfB+6zoUls5y0Uatj2zz/OodcjMcsoPVSR+VAHKXkmyDA7Eivnb4lv5njbUm9fL/APRa173rEvlwvz3NfPfjt/M8V3zeuz/0BaAMCiiigAr079mqYW/xs8NynopuP/SaWvMa9B+AcnlfFrQX9PP/APRElAH6F211FcIDGwNWAQa4PS9QKzgB+COee9dNYXwaTDHIP+FAGtVXUryOxs3nl6AYA9T6VZRg65HSuN+JM0kVra7NxBLcDueKAPBvjZNPqN2103zRngLj7nsB0r5+vozLKVHzkcfKOR9a+j/FFgt3Zu10SxYn90DjH1PrXiXiSFdPmwFA28o44H5jofagDiJbZlZg/wAgHqOlJHbq3O8YHUnirhv1UsssazAjALE8e4qo0+CeOaAL1lYM8ihURiecEjBFeveDvCulqtq9xPZyRu3zMWGVJ7HFePaVEk91GGB3MwUEnjk+9e5GCXTbe3h0+HesYX7v3X47ntQB6LZDTodMkWBrZYUO0x9CxxgdcZq34U8LC+khmEHlRqxbnoSffvXl+r2V3qslrO0i5jfy2iBBCtXr3w2v1DJbq7FIVG0gHr3BFAHr9hbrbWqRqMYFWKjtyTEpJ6jPFSUAFBAI5oooAwtS8P29xukQbXPJ968y8TeFwNQ+0xsoUAblKdDmvaHOFOK5rxDGUtHuGhjkUfeDLxj14oA8C8X6BO9tPIJUCjCAM20knqa+evGljc6ZrEsUzpKG5JXkenX1r3zxp4hkiu7m3vrKVWDkpMr7vl7ZHpXhPiC4F5qMvmMxXdhSR0oA5VeHwenvV+zn+zurEBifQ9aW6j2yMJELHOM0tvaksCGG3sp/zxQB638K/FU0WpwW9wrTwu2OWwy/Q+3pX2T4avIrvT4nt5PMiKgA9wQOhHY18K+DbaXT50muEcFhmMjBAH1r6T+EPiB31eOCNy0Mw2uD0PHBoA9vooooA/KuvSvgy+ybVAO/lf8As9ea16B8JZPLur/rz5f/ALNQB79pBJIPvXpng+P05wwP5A15hoJyy9M8d69W8G4EUz/3U/XBoA848YoiXFwT0DMCT9a8V8TzCJmMKlo8/e616v8AEG7El26pkxHOdvVj3NeS60QyurksnXg0AcHeyyliSGKE+nSs642KO5J/Kta/ikaXDMTH0B7fSqhs9jZBMh6jI4+lAGYiuVJQfKeOBWtpMU0rKCEEa+oqxFG3mBXWPceg4x7Cuj0bTiEVpFYDqwGBge5NAHV6JHBbWJYAghA5K8Aj0qTzftkbXETPtQ7NmOAarQyXDwRxwxrDCg2g4yzE8dTU2mhytz++n2KQcF+nPtQB03hfSjczJ5ijOcmvoLwbCI7aEKgyBtrw/wAManGs8cUcoEoHzgdCfrXtngy7km2IRxnOfwoA7dAAeMfhUlMRdpOSMfw/T/OadkZxnk84oAXvWbqlvujY4Bz61pVVvmAjIIyKAOZnsAynB6deK5vVNMYxvlBhiR16D6V2Rdxu4BGcYIqncIssZyCKAPCPE2huFuEkjI9DivCtesYob4xyHaSxXYTjb+PpX2Hq1mjzElQQRzx1rwT4peF0j1IziIrFKCN68Yb3H0oA8kWHyJXQscjohH3ge49auWiJ5gBI46BhyPrU0mlMicbpjFwRnlQfalkm2KgaMkjgjue1AGzbzR4VIwGbGRnkke1dFpthHeSJ5ke1xzuHFcbY5VyWxj+Agcj0rv8Aw1OI41E5wxPLnt9f8aAPTvhmGt9T8ls4mVo/qMVreKl23UpH8WG/MVT8GKP7UsypHyN1z1rS8YYE5IA+6BQB5T4jk2xsAD169q8B8Wvv8Q3jepX/ANBFe4+KZdscgz6kCvBtffzNYuWHcj+QoAz6KKKACu2+C7iP4maMx7GX/wBEvXE11/wlYL8QdKJ6fvf/AEU9AH2PpFwWnX3Fbb6gYrqEKeWb+lcdolwBKp9RU95qIXVIY93zcnA/CgD2DSHMlkjE5zzWb4stxNZScbnx8oq14YYvo8DtnLDPNc18S9XaztxawELLImWc9l9B70AfPPxC8Tpp1zKkJEshJVlPQf414vrl4b+QyEknqPQfSuz+JiKLqSRWyrPlhnofavPdsgbdHGUjx1boaAM9wUPzHJ9c9KRAWPRsetaAt48hiG3fnmomiAclzgdcelAG94N0+G71a1WclV3qSduc819DfYNLjtHkkvPMwOAnHzdhXzz4duvKu1kW3LxxkOXYnCgc9B/WuvvdY1bUbaVftf2K2kJZYoo8DAHqOe9AHfxXtlaI6LayRSzDhW+bIz1P/wBavZPhNosUdm90FI3tuHGK+aPC9retrmmma9YI22PdK5YbfpX1p4Gvw1pHCZU4+UJkZHHagDsAMDAooooAKKKKAAjI5rL1a0kntZ4lI2yIV59a1Ka+Npz0oA+Z/iL4cu5LC53ROl1agsHK9V9OK+XdTSWO5cMSZM9jnNforr2lRXcjFT8zLgEetfFfxh8MnRfFdwlsoSKQmYbeAOeR+dAHmizybSr5Y+9a+hzq10olOFPBzyD9RWbLBKCGKkqTnj1q3bgRNnnAwc9KAPWtKh2Wiwko6SdGJ7+3pXp/wu02bTNQN2CTbjCqzDBBPX8K+evDt7PDcxtuM0bNhUz1Pp7Gvqb4fyQyadbiMs6MP3isclT3BoA9mhm32ay45KbqlU7lB9RmqdkhTS0UnOE6n0qWzdTEAOAAMUAflnXY/Dmbyry5Gcbtn9a46tzwrcfZ74/7WP60AfSfhmbcEPsK9OtbkWvh64lyQSMDtkngf1rxvwbdeZHHg5xXeeJ742vhRFQ/M8i/1JoA4zxLKZlbb8zA/pXCajFGoZ2j8w9wDwD64rsL27j5YMGyuTz1NcPreoRxyeXDgs33cHjPue9AGXepE8TFlWNezZrm7y9S0zFaxLKozudhnNOvLl3kLs+dvt90e1ZuDK4QYAPegCe1kF1LumVVCnORwT+VbCarJs8mI7EQ5dupA+tZ0UGwqqIDnotK8DqzQKNm5hlj1NAHSjV5RHbxh3Kkgbq3ppCs5jRspIDtC88kZrC0uxAlTexYxKGAxwW6V1ekJFHMn2grGh4XPv7d6ANPwdaztqEbEe3JxX0d4HjWCNFfq3IrxDw7e2sN7ErRSfK2CxAA+uK908MTROYXQ7xxg46UAdtgYwelAIPQ0LkqM/jSgY6cUAFUtSQmPcKu1Tv54412yKT7jtQBlHiPaRg0x2Q2spIxIOBxkVZaRJB8pVh39arvGCrBce+aAOWkyrOGAKEY+lcX4x06PUdNlhfBODtb0NegatatHDJIF4INcJqyny5FccAZNAHgd0gDTRv8lxC2xh69qrSWySqgljzIAfn6MP8APvW54vjhstSa5bftlX5lA6Ed6yoZo1HnAsYiBwAMn6mgBbPSmhXz8hozyM9j7ir0FyiOF3EMeuR1pY76Ap+7yQ3JHH+c1nzpGzuVkCOOT6UAetfDrV1F9DCzAAMvlknpz0rsvG8mLuToFxn868A0vWWtLq2gDbZ96scdueK9y8T3S3elQXqZxKgY/iM/zzQB4x42utkcmWwQpxXil8++6kYnJJ/pXpXxEvCvmKDzz0ry923MT60ANooooAK3PBV8uneKtOunOFSTDH0DAqf51h0+I4fI9D/KgD660288pFbec+ueKtaNcpdeJJAW3GMAH8cmvINK8aBvDtqzn98EAc+4610Pw28RC91e4fcAWfjPPQUAfXWggJpUPptzXl3xfeS4CPbhmdegHvXomi3HmeFhImeI2A59q8/8UtHPaOjkYdPnfPTHv7UAeC6hp9rKHe/uA054I2bgPYDvXBeILCG0Ynzjs6hSORntXTeLfECW928WnpuuEcqZXGR/wEf1Nefajdy3ju88haQk7iTyfrQBUnu4xxErBh/EDT9Pk3XqSFjkHJLDNUDGc4ANWbeFnIjRTlhQB0kWru1xFDCV+y2+TyOHb6V0el6m+oXdvFsUgRkFVGN3YVxej2nm6jFEzHyw2Dt7/jXoXhyyS1jmZIwj5yHY4CKv+12oAdZW1/carbIkMmyOXY2OF47V9Q/DnSJktonn+VUAwOuK8J0TXLKKOKdY2vbpJR5ojbamfXJ5P4V9LeC9UhvdPj2QrASvAU5FAHTUUUUAFFFFABQelFFAGPcRMXkKgiQjAPrXhHx/8PG50o38cZLQ4cgDqO9fQV8jJC7LnjkbeorznxpcmfT3i6EAoQehzQB8ZSwxLEwYZJ+ZCDyPwqCWxEsgZ8rwAHHGD7+tavijQpdM1u9tjLGHifzEXdyVPPFR6JdATRLfQ7AhI81vmP4r3FAF3w/p09m8dxKp8s/6th0+v19BXsXgvW3s9QieEDYMCWPpuHp/WubWZJLVWgaKZJewAwfUf/WqXSIpLa9hkiJaAtl8jlR1P4fyoA+u4JFl0uOSM5Vogw/KqNhcYjGTyCQfzrM8CXhuvDDAtkx7sfTGf8ao2N8GaZd3AdhQB+ctWbCUxTgiq1KpIIIoA958CXRMMZznOD1rr/iNfmDw1aKGAZsvknoBj/69edfDaQzpBFyMkDNX/jbqfyW1jGflCYkx6HBA/rQBxE3iszbrdHPlD+LoWqKe8iliwzfeH5VxT5DEHrVm2u3jIVjhfWgDYcHzBkHHQZ5zU8Vk8pR2iWOIc4BwSagiuEAUoFL4+U4zWi0xgi/ekMSefQGgCX/VHCgBmGT3IHpmr+n2ayXqeefLTAyTz+Vc/wCaLmbnIU/xe1aNvK8V55UfRMgk9xQB0JvDHqXl2SqI1bYX4ORVy2VjfO8mThQVLEn8KwvLWCSN0QszDeNx+6fSulQeaFIXBYAk0AdDo7efGh/iUgFs45r3D4d3glkh3HOBj8fSvENIhJZY4ckZHQV7H8PtPeEQM7/NnJJP6CgD19CSuTTqghK+X0OF465qVCCPlOcUAOrF8RSGJAQevFbVYvimHzbEEHDqdw+lAGCtyA+8nH0q9BeI6sZc7B1I71ys8zRthvX1pp1IxwEE4BNAHT3kiSwMgPyN0Jrz/wAQWSSOWk+QqSR1wMjHIFaz6mDbna3A9+9YGt6tA8bNI2CowaAPJvG0CQzIshyoYgkjhlxXCC6W0ZoA6vHg4OM571u/ELXElvBHEykx84J4rzq/uMyGSNxh+mTgfSgDRn1LypsrkFfypX15JB8+VmXoOzVzN1d+aq7chhwT61UJOc55oA66yunmvI5S2Z8g+1fQdhqBvfAts27lEIH4Mf8AGvmLR7ki5UOfm7H1r6E8Jv5ngoMAMqWVh6ZGaAPIPiHITOwPdjXC12/xE/4/SOwHSuIoAKKKKAClXrSUooAsQ3ckULRqx2k5xXY/DLVPsmrIGbGWrha1PDspi1SEqTnNAH394c1HHw+uJNyjO4Lk+3P6ZrwfxX45W7kktbZi1ryFbP3z3J9vSk+MPii58N/D7RtI064aK7ldZJCDzsXg/m2R9Aa8Sk1lL23yPkk/jTPT6HuKANvxOI7jFwpAc8Fs8GuPKMZvmBwfatCzvWl/dSbQg6u3ar1z5UbqbSNee2M59yTQBWtbJJfLZ1IRT9zPU/1q1f2vkyiNdm/hWZWHX0FVri+SCMICHkBzwOKz1kaeYGYnbnNAHQaDbiG6mmkxiNflGflJ9Ca0NOFzqc0stw5KkfKuflB+nQVh6bdlpWUp+6ICMoHUetb2jSJBe7IYlEW4oS3JYeuaAOi0Nls4oyz4aT7wx1A4B+lfQ3wov3mgh3krIuUPPBxXzxZWs15fLIF8sD7vHDY9K+hPg/poinkdmJUDdhvU9P0oA9gHIFFA4GKKACiiigAoprnHqfpUck6rGSSBzj8aAJHAdCOxrhvGFhFcWzgsiSZJBI5Ptx1rq7i4Xys7iBnqK4vxRq0cKF5SNv8Ae9PrQB8s/F/RZDqCXCqqlY8FgeoB6H35rhHMccEbuTuyBvXnHt716N8T/E9hdayUtn37QVfb/L6V5dKMPtZSscnK+g96ANDTNVm06V2ikJVuCjfdPvXpngrXlu280OQ4wGiPJAH8/rXiJmZZdjHgHkHirH9tXEDf6G5icDbvTg49KAPtb4O6/Fd6hqVpBIGto4Rt5zht3I/U1Gl+Ir+9iLAFX9fqP6V45+zHrLSeIri13YE9uY+f4WAJH8q6a8vZU8R6qJGwd+MZ6fMwNAHyhRRRQB678I23TRgn7qkj+X9apfE6Zp9avnI4EzKB7A4H8qd8JZiso55wR/I/0qv8QgRrt/EQBvlZh9Cc/wBaAPOJB87fWmVZuVVTgY44qvQA+KVonDIcEVuabbX+qyB9gKEgAk4H4CtLwp4Qn1GRZLhCFPIU/wAzXtHhzwrFaiLdGOny8Y/GgDgdP8EvHsF2Ljc43fIABitu08ERqHdEuGfpknnJr1zTdC80KNpODxkdK6yx0GGJACgZup9qAPAIvh/q0qsbZAAuNhlGTW9Z+BdQFrGLlgHXHG4YI79K90isGjU58uRF4O4kMPyGD+lVbmw8xjgBlbtjGKAPO9L0f7IqpHHGxzyx9a9L8LjLxLJHhsgfIeB+dUY9NKEbuh9q6nwxa7J8kDgZ/GgDqEUKuFHFKD8xG0jHf1paQ9uRQAtYnii6+y26Nt3A5B5rbrE8WQ+bYJxn5sGgDz65mjdy6cg8EHqDWPelUSME+pwPX1rZk0nMpdZWXtjGc0Dw4sse5rhwQemKAOK1G82WLlCBz3PX6V4/4v8AE1zFK6xzMoOV619A6p4HFxH808+CeVUD9K898TfCGC+kLx3tyhPQbVoA+aLy6nkuXd5nYk9Se1VSxIwSa9l1n4NzQuzJczEqOnljFcZqvw91WzEjw7ZVTt0agDjdvvxTat3dvNaysl3E8UvYEYz71V60APhBMiqCeTX0T8N5zdeBL9CfnRwD+C5/UV8+6cgafnt0r3f4XsYdFvYjnaUVj9dwH8jQB5X8QpM6mV9ea5GtzxhN5utS88LxWHQAUUUUAFFFFABWt4UAbxLpiuMobmPcPUbhmsmruiy+Rq9nKeAsqk/nQB3vxs1B7vxLDGzErFZQKPqyCQ/q5rzbJByK7T4pEvr1tL2lsoD+KrsP/oNcWaALSXbbFUjgelWY7pjkhseg7ms1RXUeFvDd3qVyjJGwAI5A6UAW9D8H6prJSSNBEsp+UuDlvfA7V20XwivklEMt4GyobdGOD7V6T4M8PXtpEim4l3lACCAdo9M4r0/Q/CdxNsN3LJtznAODQB87r8Hr5Ik8mc7ydx38AVqad8NdUtXtnW1e8dW+YwqQox6k19U2uhWluigRL8vAJ5NXZbVWt/LC7VbqBQB84R+Hry0vRKttIZMAiIkbVb3Pce3516T4KTVraWNnlAUj50KDB/Cuwl0SInJAAB4IHarthp6QEYPtQBroSUBPUiloooAKDwM0UNyDQBRe+VXw7Ko7H396z9UuVjiUsDuJPIOMf41R1Gyv3lYwRqwGSBnGTWeLLWUt8Sxxugb5Q0g+X3oAp634jgtLAq86xPkn5+PxzXz18SPiOX8+1tpEkjcEEhs4z3GK9j8X+H5b61MdxqmnRLIDu3SEnHsMV80eNfhvfabcyTDVdPuLcsdsg3g49+KAPOZ7hjIx3HcTnOetD3jOpDc5xjHars2gXahtjwykHGEfms25tJ7ZsXETxn/aGKAGSytIctgfSox1pTQBkgCgD0r4Cal/ZfxB0ySRtsEsnlyewPAP4H+Zr1Hx7N/Z/jPVCTtWSITD67uf1zXhXhCUwXiSJkOCAPbmvXPjXeD/AISEODh3tmDD335/rQB890UUUAd/8L5tt1gdVYEVv/FW0+z6it2PuzRrz+H/AOuuP+HU4j1XafrXpvxdtfP8PaaQDkoAxHZeuf1oA8NcNcThIkLsTgAdTXo/w+8BPeSJcXyBu4Ujgf8A16s+AvCfmkSmJc5AyfSvdfDmkLaxIoXj6UAUdA8NRW0KjaC3fiuy03Rc4Zh16ACtPTrAYXK/XiugtbVQANvOMYoAqafpyxhQoAx1rUjtS5IHA9au2tphcHnNaUcAHPQ0AZK2P7vbjI70hsgP4frW4EXbjFKVB7CgDnTp4DhlBBJ6YrY0+2+zx8j5j1qztABwKq31zDp9rPe3sqw2tvGZJGOSFUDJPFAFyiuf0XxjomtabPfWF1IYoJlt5Ult5IpUkbbsUxuoYFt64453DFLpvi/RNS8Q3OiWl4W1KDfujaF0VthCvscqFfaSAdpOM80Ab9VdSiE1o6ntzWDfePvDVjfWNpdamqTXgDRfunKhS+xWdguEVm+VSxAJ6ZqWDxj4evfEkvh2LUI5NUQsph2NtLoAzIr42s6gglQSRkZFAEaadu6DFW49MKk4XpyK2I4UQ/KKkoAw5oY412vz3xXm+pX+rXXxEj0+2tJF0ezszPc3DIVSSV87VDdGIwvHBHzHOOD65c2yzA9jWPcabLu6E9sjoKAONngjlZhLGNuOi9axtU8LwXETNCmSfzHeu/bQJg25SQR3qePSPIhw3L9T7UAfN3jXwEmoWMnmwAuucNjkV8++JPD9zo106OrGLPDHt9a+9dW0ppEcw7VkwdpYZGfcd/8APIryjxr4QgvNPlbyk8xsnp09R+eaAPmLTbXc0TKCdhwRXsnhP/RvDuoXHQBVUfqT/IV57HpraTqdxayjgNlf8+1ek6hCdJ8AJG2VkmTzWB/2un6UAeB6vKZtRnc92NU6luTuuJD6saioAKKKKACiiigAp8RxIp6c0ylHBoA9B8fWxufCug6wOh3W7Y9cbv55rz4Ak8CvUdYkST4I6erAGQ3xdfYcg/y/WuV8F6BJrF+qgfKO9AGt4B8DXWvSCZgREp496+k/BngiKxt41SMFzjnGSTUfw+8Px6bZQ28SgluSQK9l0XTUhjX5ck8mgCroPh2G1jVnQGQ9a6iKJY1AUdKWNdqgelPoATApaKKADHPWiisVvEunjxKdBQzyagqK8gSFmSMMGK7m6DIU/p6igDaorm9f8Z6ToMJl1A3WwGUsYrd5NiRY8yQ7QcIu4ZP5Zq63iPSxr9rooud2o3MDXEcaoxGwY5LYwOowCcmgDXormdV8caJpdzDBeTzK0imQlIWdY4xJ5fmOyghULcBj9egNaceu6bL4hl0OK6R9UhgFzLAuSY4yQAWPQZzwOvegDSKg9RVa+tPtMbKrlCRgegq1RigDyfxN8PdY1CVjb3FuycYBJGfc+9c7d/BXU7+Fln1CGPdycsSD7YxXvVFAHy5qH7Nd4CzQapbupOcbWyPao7n4OXsOl/Y75/tcSDCFh8y/Q9/xr6nqN41fh0UigD87PHPw+v8Aw/cyMsTGAdDiuHClHw4IPvX6KeLvBNrq7F5YkKHPy44NfL/xg+GRsbee+0+Da8I3ui/3R1oA838F2jXeuafAg5mnSP8ANhzXWfGTUPO8YXCqflWHA/Fif5YqH9n/AE86j4wllYZSwtJbjPo2ML+pz+Fcx4/vvtXie+mzw2cfQcD9BQBx9FFFAGp4cuDb6vA4OMnBr6B8QW7apo+nsiF1MZQhRnrjH86+b7V/LuYmHZhX1B8OrhL7Q4EYjcgGD/n2/lQBt+F9CWx0+3jYfvFUAn3rv9IsFGWxzjFZOlQkSAMOnGK7CxjzhVHTrQBZtoNrKFGMVr2cA9/c0yztvu9M1rQRBckUASRRhV6c1JQMHpRQAUUUUAFVNWtp7zTLm3tLyWxuJYysdzEqs0TdmAYEHHoRVuigDhPCfgWfQmlafUkumu9TOp3SxwmGIyeXtGxNzYywDtknJGRim/8ACEar/wAJXda/L4gFxdLZ3FnZA2ojZUkbcqysp+dUP3cKp9STXe0UAeb+NfhbbeJbvTQt3Ha2UEENtOBCxnljikDqPMDgdV/iVsZJGDWjY+DtTj8fyeIdQ1ezvbUGQW1q9hta0VhgiJw+AW43MVLNjGQMCu3ooACOnXiiiigAAAooooAKbIgZSKdRQBl3dsgUnGa47xHZrJGQFGD/ACrvrpA0ZPWuW1iPMbfSgD5n8b+HfM8X6cI1xDMwDt6DODTPjHdrBBPbp8qqoQAHpwK9U1zTEmuYXdRmGTfn6cmvnv4w6sJtQuUBYEEgZHXtketAHlDHLE+pptFFABRRRQAUUUUAFFFFAHoemxz6r8PrO1t0MrW15yg64YP/APWr2P4deDY9I0m1Eu1rphudl6c9q8l+C92Df3Fi5H7zDLn+8OR+ox+NfT/hy0WWSBowfLwCQex9KAOs8MaWkUSsyjdiuxtkAwFBxWbp8YYBUHyjgmtuJAigAUAPooooAKKKKACuX1Twda6j4ptNanu7jdbOs0duqRBfNVSqsXC+ZjDH5d20+ldRRQByPiPwWNbsNNtDrF9aRWbGQrCkTJPIed0iSIytg5IBGMnPYU6XwNpx8TweIIJryLUovNYn7RI0ckkiKm8xltowFHCgA9+gx1W0+bu7bcU6gDjvE3gDTvEI05LyVlhtYxCyCGMmVNysRvKllyVGcEd+/Nbp0WE+KF1vzZPPWzNkI+Nu0uHz65yMelalFABRRRQAUUUUAFFFFAAQGBBGRXGeNNFiubWTMQffwVPcHtXZ1DdRCWMggUAfJ3w98MHwXrPi6Bx8r20hjc9PLH3cfgxzXzprs/nanO+epr7M+Lxh0bw1rd4gw7wmBGPU56/qR+VfE1y2+Z29SaAIqKKKAHIcMD719A/CW9H2RFY8AYNfPlet/Cq/2uig8HHegD6csEAaPYcllBPtXX6UgVAOtee6Zct9pQcfdFd1pE5IAPTp1zmgDqLRcAc9qur3yfpxVCzYNgegrQFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAnO72paKKABuQa5zWURCSxzjoK2bq48sZHP0rlvEt2fs7uhXdkYzyPegDgvG18tlZyyZwxXj2r488bagb/WZDnKqTivoj4tar5enyBX5wRjNfLl5IZbmRz1JNAENFFFABRRRQAUUUUAFFFFAHS/D+7Nn4kt5educMPavtrwjNBJpNsy/I853rz2wOfyxXwNa3MtrMssD7JF6HAP867O0+LHjWz8r7PrRTykCJ/osJwPTlKAP0L0uJUiG0jArQr8/Ifj58SoV2xeJMD/AK8bY/8AtOpP+Gg/if8A9DN/5IWv/wAboA+/wMADrRXwB/w0H8T/APoZv/JC1/8AjdH/AA0H8T/+hm/8kLX/AON0Aff9FfAH/DQfxP8A+hm/8kLX/wCN0f8ADQfxP/6Gb/yQtf8A43QB9/0V8Af8NB/E/wD6Gb/yQtf/AI3R/wANB/E//oZv/JC1/wDjdAH3/RXwB/w0H8T/APoZv/JC1/8AjdH/AA0H8T/+hm/8kLX/AON0Aff9FfAH/DQfxP8A+hm/8kLX/wCN0f8ADQfxP/6Gb/yQtf8A43QB9/0V8Af8NB/E/wD6Gb/yQtf/AI3R/wANB/E//oZv/JC1/wDjdAH3/RXwB/w0H8T/APoZv/JC1/8AjdH/AA0H8T/+hm/8kLX/AON0Aff9FfAH/DQfxP8A+hm/8kLX/wCN0f8ADQfxP/6Gb/yQtf8A43QB9/1HcHELE9Mcn0r4E/4aD+J//Qzf+SFr/wDG6ST9oD4mujK3ibKkYI+wWv8A8boA9h/ae1cJpDWsTfIWH+f5/nXyWeprovEvjXxB4mAGt6gboA5/1Maf+gqK5ygAooooAK6/wBfm2v0XdjDetchU9pdTWknmW77H9cA/zoA+vfDd35kcLkk9M59K9H0ibKLzXxDZfETxTZRhLbVNijoPs8R/mtakPxj8eQYEWu7cf9OkB/8AZKAPvrT5MIpzzWvG25c1+fUfx2+I8Y+TxFj/ALcbb/43U4/aB+JyjjxN/wCSFr/8boA/QCivgD/hoP4n/wDQzf8Akha//G6P+Gg/if8A9DN/5IWv/wAboA+/6AAM18Af8NB/E/8A6Gb/AMkLX/43R/w0H8T/APoZv/JC1/8AjdAH3/RXwB/w0H8T/wDoZv8AyQtf/jdH/DQfxP8A+hm/8kLX/wCN0Aff9FfAH/DQfxP/AOhm/wDJC1/+N0f8NB/E/wD6Gb/yQtf/AI3QB9/0V8Af8NB/E/8A6Gb/AMkLX/43R/w0H8T/APoZv/JC1/8AjdAH3/RXwB/w0H8T/wDoZv8AyQtf/jdH/DQfxP8A+hm/8kLX/wCN0Aff9Ga+AP8AhoP4n/8AQzf+SFr/APG6Q/tA/E0sGPiUFl6H+z7Xj/yFQB+gFVJJtoIY818Fn9oL4nHr4m/8kLX/AONVC3x6+JLElvEnP/Xjbf8AxugD7h1O62qxP0ridZvy1ncEsAA2Bn+lfJsvxu+IUoxJ4hJH/Xnb/wDxus64+KnjO4UrNrJYHr/o0I/klAHY/FjVvNa4TIOAQPrXjB5NaGp6zqGpsWvrgyknJ+VV/kBWdQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Young woman with acute onset of erythema nodosum and no respiratory complaints. Left: The chest radiograph shows bilateral hilar adenopathy (Stage I). Right: A follow-up chest radiograph on no therapy is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25013=[""].join("\n");
var outline_f24_27_25013=null;
var title_f24_27_25014="Timolol (ophthalmic): Pediatric drug information";
var content_f24_27_25014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Timolol (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=see_link\">",
"    see \"Timolol (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=see_link\">",
"    see \"Timolol (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betimol&reg;;",
"     </li>",
"     <li>",
"      Istalol&reg;;",
"     </li>",
"     <li>",
"      Timolol GFS;",
"     </li>",
"     <li>",
"      Timoptic-XE&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg; in OcuDose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Timop&reg;;",
"     </li>",
"     <li>",
"      Dom-Timolol;",
"     </li>",
"     <li>",
"      Mylan-Timolol;",
"     </li>",
"     <li>",
"      Novo-Timol;",
"     </li>",
"     <li>",
"      PMS-Timolol;",
"     </li>",
"     <li>",
"      Sandoz-Timolol;",
"     </li>",
"     <li>",
"      Tim-AK;",
"     </li>",
"     <li>",
"      Timolol Maleate-EX;",
"     </li>",
"     <li>",
"      Timoptic-XE&reg;;",
"     </li>",
"     <li>",
"      Timoptic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10536947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10536964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=see_link\">",
"      see \"Timolol (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel (Timoptic-XE&reg;): Adults: 0.25% or 0.5% gel, instill 1 drop once daily; do not exceed 1 drop once daily of 0.5% gel",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution (Timoptic&reg;): Children and Adults: Initial: 0.25% solution, instill 1 drop twice daily; increase to 0.5% solution if response not adequate; decrease to 1 drop/day if controlled; do not exceed 1 drop twice daily of 0.5% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution (Istalol&trade;): Adults: Initial: 0.5% solution: Instill 1 drop once daily in the morning",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel forming solution, ophthalmic, as maleate [strength expressed as base, drops]: 0.25% (5 mL); 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timolol GFS: 0.25% (5 mL); 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timoptic-XE&reg;: 0.25% (5 mL); 0.5% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hemihydrate [strength expressed as base, drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betimol&reg;: 0.25% (5 mL); 0.5% (5 mL, 10 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as maleate [strength expressed as base, drops]: 0.25% (5 mL, 10 mL, 15 mL); 0.5% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Istalol&reg;: 0.5% (2.5 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timoptic&reg;: 0.25% (5 mL); 0.5% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as maleate [strength expressed as base, drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Timoptic&reg; in OcuDose&reg;: 0.25% (0.2 mL); 0.5% (0.2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes solution as maleate (preservative free), solution as hemihydrate",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10536965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops; avoid contact of bottle tip with skin or eye. Remove contact lenses prior to administration (ophthalmic solution contains benzalkonium chloride which may adsorb to soft contact lenses); lenses may be inserted 15 minutes after administration. Gel: Invert container, shake once before use; administer other topical ophthalmic medications at least 10 minutes before Timoptic-XE&reg;",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10536953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drops: Store at room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze. Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timolol GFS: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timpotic&reg; OcuDose&reg;: Store in protective foil wrap; use within 1 month after opening foil package",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10536948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9600171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Timolol may be confused with atenolol, Tylenol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Timoptic&reg; may be confused with Betoptic S&reg;, Talacen, Viroptic&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bottle cap color change: Timoptic&reg;: Both the 0.25% and 0.5% strengths are now packaged in bottles with yellow caps; previously, the color of the cap on the product corresponded to different strengths.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betimol [U.S.] may be confused with Betanol brand name for metipranolol [Monaco]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9600212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris, arrhythmia, bradycardia, cardiac arrest, cardiac failure, cerebral ischemia, cerebral vascular accident, edema, heart block, hypertension, hypotension, palpitation, Raynaud's phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, depression, disorientation, dizziness, hallucinations, headache, insomnia, memory loss, nervousness, nightmares, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, pseudopemphigoid, psoriasiform rash, psoriasis exacerbation, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia masked, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, retoperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Claudication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myasthenia gravis exacerbation, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharitis, blurred vision, burning, cataract, choroidal detachment (following filtration surgery), conjunctival injection, conjunctivitis, corneal sensitivity decreased, cystoid macular edema, diplopia, dry eyes, foreign body sensation,  hyperemia, itching, keratitis, ocular discharge, ocular pain, ptosis, stinging, tearing, visual acuity decreased refractive changes, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, nasal congestion, pulmonary edema, respiratory failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, cold hands/feet, Peyronie's disease, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10536949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to timolol or any component; uncompensated CHF, cardiogenic shock, bradycardia or heart block, bronchial asthma, severe chronic obstructive pulmonary disease or history of asthma, CHF or bradycardia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10536951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with a miotic in angle-closure or narrow-angle glaucoma; multi-use ocular products have been associated with bacterial keratitis; avoid touching tip of applicator to eye or other surfaces.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10536950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe CNS, cardiovascular and respiratory adverse effects have been seen following ophthalmic use; same adverse reactions seen with systemic therapy may occur with ocular therapy. Some products do contain benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9600214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies; therefore, the manufacturer classifies timolol ophthalmic as pregnancy category C. Timolol crosses the placenta. Decreased fetal heart rate has been observed following maternal use of oral and ophthalmic timolol during pregnancy. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. If timolol is required for the treatment of glaucoma during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease exposure to the fetus. Also refer to the Timolol (Systemic) monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10536966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor IOP",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10536954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors; reduces intraocular pressure by reducing aqueous humor production or possibly outflow",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10536955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure reduction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10536956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Timolol is measurable in the serum following ophthalmic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes into human breast milk",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10536967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=see_link\">",
"      see \"Timolol (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential visual disturbances from ophthalmic use may impair ability to perform hazardous duties such as driving or operating machinery",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10536969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lowest effective dose in pediatric patients. Children had higher plasma concentrations vs adults; some achieved therapeutic levels; this may result in increased adverse systemic effects. The concurrent use of 2 ophthalmic beta blockers is not recommended.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hoskins HD, Hetherington J Jr, Magee SD, et al, &ldquo;Clinical Experience With Timolol in Childhood Glaucoma,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1985, 103(8):1163-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25014/abstract-text/4026647/pubmed\" id=\"4026647\" target=\"_blank\">",
"        4026647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16056 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-A7765D755B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25014=[""].join("\n");
var outline_f24_27_25014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600186\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600187\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536947\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536964\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600295\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600189\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536965\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536953\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536948\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600171\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600212\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536949\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536951\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536950\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600214\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600215\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600191\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600192\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536966\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536954\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536955\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536956\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536967\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10536969\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16056|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/60/28615?source=related_link\">",
"      Timolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/13/30932?source=related_link\">",
"      Timolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27287?source=related_link\">",
"      Timolol (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/60/22469?source=related_link\">",
"      Timolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/9/16534?source=related_link\">",
"      Timolol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_27_25015="Vigabatrin: Pediatric drug information";
var content_f24_27_25015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vigabatrin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=see_link\">",
"    see \"Vigabatrin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/38/614?source=see_link\">",
"    see \"Vigabatrin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11238848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8107369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sabril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sabril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1042182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Infantile Spasms, Treatment",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1042214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=see_link\">",
"      see \"Vigabatrin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Infantile spasms:",
"     </b>",
"     Infants and Children 1 month to 2 years of age: Oral: Initial: 50 mg/kg/day divided twice daily; may titrate upwards by 25-50 mg/kg/day increments every 3 days based on response and tolerability; maximum dose: 150 mg/kg/day divided twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     To  taper, decrease dose by 25-50 mg/kg/day every 3-4 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Refractory complex partial seizures; adjunctive treatment:",
"     </b>",
"     Limited data available: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;10 kg and Adolescents &lt;16 years: Initial: 40 mg/kg/day divided twice daily; maintenance dosages based on patient weight (Camposano, 2008; Coppola, 2004; Willmore, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     10-15 kg:  500-1000 mg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     16-30 kg: 1000-1500 mg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     31-50 kg: 1500-3000 mg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;50 kg: 2000-3000 mg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &ge;16 years",
"     <b>",
"      :",
"     </b>",
"     Initial: 500 mg twice daily; increase daily dose by 500 mg increments at weekly intervals based on response and tolerability; recommended dose: 3000 mg/day divided twice daily;",
"     <b>",
"      Note",
"     </b>",
"     : To taper, decrease dose by 1000 mg/day on a weekly basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Refractory complex partial seizures; adjunctive treatment:",
"     </b>",
"     Initial: 500 mg twice daily; increase daily dose by 500 mg increments at weekly intervals based on response and tolerability; recommended dose:",
"     <b>",
"      3000 mg",
"     </b>",
"     /day divided twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     To taper, decrease dose by 1000 mg/day on a weekly basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50-80 mL/minute: Decrease dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30-50 mL/minute: Decrease dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10-30 mL/minute: Decrease dose by 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustment provided in manufacturer's labeling; has not been studied; however, does not undergo appreciable hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sabril&reg;: 500 mg/packet (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sabril&reg;: 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Vigabatrin is only available in the U.S. under a special restricted distribution program (SHARE). Under the SHARE program, only prescribers and pharmacies registered with the program are able to prescribe and distribute vigabatrin. Vigabatrin may only be dispensed to patients who are enrolled in and meet all conditions of SHARE. Contact the SHARE program at 1-888-45-SHARE.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8104264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM180720.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM180720.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1042220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May be administered without regard to food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for oral solution: Dissolve each 500 mg powder packet in 10 mL of cold or room temperature water to make a 50 mg/mL solution; discard solution if it is not clear (or free of particles) and colorless. The appropriate dose aliquot should be administered immediately using oral syringe (provided). Any remaining liquid should be discarded.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1042203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablet and powder for oral solution at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1042183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral solution: Monotherapy for treatment of infantile spasms in patients for whom the potential benefits outweigh the potential risk of vision loss (FDA approved in ages 1 month to 2 years); has also been used in children as adjunct therapy for refractory complex partial seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:  Adjunct therapy for refractory complex partial seizures not controlled by usual treatments in patients for whom the potential benefits outweigh the potential risk of vision loss (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8308547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vigabatrin may be confused with Vibativ&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F234058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal behavior, abnormal thinking, aggression, anxiety, confusion, coordination impaired, depression, disturbance in attention, dizziness, fatigue, fever, headache, hypoesthesia, hypotonia, insomnia, irritability, lethargy, memory impairment, postictal state, sedation, seizure, sensory disturbance, somnolence, status epilepticus, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contusion, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea, fluid retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, abdominal pain, appetite decreased/increased, constipation, diarrhea, dyspepsia, hemorrhoidal symptoms, nausea, viral gastroenteritis, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, dysarthria, extremity pain, hyper-reflexia, hyporeflexia, joint swelling, muscle spasms, myalgia, paresthesia, shoulder pain, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis, diplopia, eye strain, nystagmus, strabismus, visual field constriction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, nasal congestion, pharyngitis, pharyngolaryngeal pain, pneumonia, sinus headache, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Candidiasis, croup, influenza, thirst, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute psychosis, angioedema, cholestasis, deafness, delayed puberty, delirium, encephalopathy, facial edema, gastrointestinal hemorrhage, hypomania, laryngoedema, malignant hyperthermia, multiorgan failure, optic neuritis, pruritus, psychotic disorder, pulmonary embolism, respiratory failure, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1042189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vigabatrin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7407982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dose in patients with renal dysfunction. Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; vigabatrin should be withdrawn gradually to minimize the potential of increased seizure frequency; to withdraw therapy in infants and children, decrease the dose by 25-50 mg/kg/day every 3-4 days; in adults decrease the dose by 1 g/day every week. Vigabatrin should not be used as monotherapy or first line therapy for complex partial seizures. Use with caution when initiating therapy, particularly in patients with myoclonic seizures, as an increase in seizure frequency or onset of new types of seizures may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dose-dependent, asymptomatic MRI abnormalities have been reported in infants treated with vigabatrin for infantile spasms; resolution of abnormalities generally occurs upon vigabatrin discontinuation; abnormalities resolved in a few infants, despite continued use; some infants displayed coincident motor abnormalities, but no causal relationship has been established; risk for long-term clinical sequelae has not been studied. Animal models have shown intramyelinic edema in the brain; current evidence suggests that this does not occur in humans; however, patients should be monitored for neurotoxicity. A relationship between MRI abnormalities in infants and animal model findings has not been established. In adult patients, peripheral neuropathy manifesting as numbness or tingling in the toes or feet, reduced distal lower limb vibration or position sensation, or progressive loss of reflexes, starting at the ankles, has been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Anemia has been reported; in some cases with a significant reduction in hemoglobin (&lt;8 g/dL) and/or hematocrit (&lt;24%). Somnolence and fatigue can occur with use; higher incidence reported in infants compared to adults (infants: &le;45% ; adults: &le;24%); patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). May cause fever; higher incidence reported in infants than adults (&le;30% vs 6%). May cause vomiting; higher incidence in infants (up to 20%). Peripheral edema independent of hypertension, heart failure, weight gain, or renal or hepatic dysfunction has been reported; in adults, an average weight gain of 3.5 kg has been associated with use. Vigabatrin has been reported to decrease AST and ALT activity in the plasma in up to 90% of patients, causing the enzymes to become undetectable in some patients; this may preclude use of AST and ALT as markers for hepatic injury. Infants may experience a higher frequency of other adverse effects than adults, including vomiting and upper respiratory tract infections.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1042190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Vigabatrin causes permanent vision loss in a high percentage of patients, including infants, children, and adults. Vision loss is most frequently described as progressive, bilateral concentric visual field constriction; decreased visual acuity has also been reported. Neither type of vision loss is reliably prevented through periodic vision testing. There is no known exposure level of vigabatrin without risk of vision loss; however, risk has been shown to increase with total cumulative dose or duration of therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . The onset of vision loss is unpredictable, occurring within weeks of starting treatment or sooner, or at any time during treatment, even after months or years of therapy. It has also been reported to worsen despite discontinuation of therapy. Most information characterizing frequency and extent of vision loss is from adult data since vision loss assessment is difficult in infants and children. Vigabatrin causes permanent bilateral concentric visual field constriction in &gt;30% of patients ranging in severity from mild to severe, including tunnel vision to within 10 degrees of visual fixation, and can result in disability. In some cases, vigabatrin can damage the central retina and decrease visual acuity. In infants and children, symptoms of vision loss are unlikely to be recognized by the parent or caregiver until loss is severe. Vision loss of milder severity, although potentially unrecognized by the parent or caregiver, may still adversely affect function. Vision should be assessed to the extent possible at baseline (no later than 4 weeks after initiation), at least every 3 months during therapy, and at 3-6 months after discontinuation. Once detected, vision loss is not reversible. Due to the risk of vision loss and because vigabatrin provides an observable symptomatic benefit when it is effective, the lowest dose and shortest exposure consistent with clinical objectives should be used. If the patient fails to show substantial clinical benefit within a short period of time after initiation of treatment (2-4 weeks for infantile spasms; &le;3 months in adults), vigabatrin therapy should be withdrawn. If in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier in the treatment course, vigabatrin should be discontinued at that time. The interaction of other types of irreversible vision damage with vision damage from vigabatrin has not been well-characterized, but is likely adverse. Vigabatrin should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks. The possibility that vision loss from vigabatrin may be more common, more severe or have more severe functional consequences in infants and children than in adults cannot be excluded. In the U.S., vigabatrin is only available under a special restricted distribution program (SHARE)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Under the SHARE program, only prescribers and pharmacies registered with the program are able to prescribe and distribute vigabatrin. Vigabatrin may only be dispensed to patients who are enrolled in and meet all conditions of SHARE.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA requires a Medication Guide for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Vigabatrin may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Vigabatrin may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1042202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     In adults, food decreased the maximum concentration by 33% and increased the time to peak to 2 hours; no change in AUC was observed",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Vigabatrin crosses the placenta in humans (Tran, 1998). Birth defects have been reported following use in pregnancy and include: cardiac defects, limb defects, male genital malformations, fetal anticonvulsant syndrome, renal and ear abnormalities. Time of exposure or maternal dosage was not reported and information is not available relating to the incidence or types of these outcomes in comparison to the general epilepsy population. Visual field examinations have been conducted following in utero exposure in a limited number of children tested at &ge;6 years of age; no visual field loss was observed in 4 children and results were inconclusive in 2 others (Lawthorn, 2009; Sorri 2005). Use during pregnancy is contraindicated in Canadian product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to vigabatrin during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1042222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmologic examination by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina at baseline (no later than 4 weeks after therapy initiation), periodically during therapy (every 3 months), and 3-6 months after discontinuation of therapy; assessment should include visual acuity and visual field whenever possible including mydriatic peripheral fundus examination and visual field perimetry. Observe patient for excessive sedation, especially when instituting or increasing therapy; frequency, duration, and severity of seizure episodes; hemoglobin and hematocrit; renal function; weight; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes), neurotoxicity, peripheral neuropathy, and edema.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F9837874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A correlation between serum concentrations and efficacy has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1042205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irreversibly inhibits gamma-aminobutyric acid transaminase (GABA-T), increasing the levels of the inhibitory compound gamma amino butyric acid (GABA) within the brain. Duration of effect is dependent upon rate of GABA-T resynthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F7408004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A correlation between serum concentrations and efficacy has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of action: Variable; dependent on rate of GABA-T resynthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1042207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid; bioequivalence established between tablets and oral solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Tablet and oral solution are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 1.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:  Does not bind to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Infants: 5.7 hours; adults: 7.5 hours; prolonged in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Infants: 2.5 hours; children and adults: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (80% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: 2.4 &plusmn; 0.8 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 5.7 &plusmn; 2.5 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 7 L/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Effect of dialysis has not been adequately studied; in case reports, hemodialysis decreased vigabatrin plasma concentrations by 40% to 60%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1042223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/38/614?source=see_link\">",
"      see \"Vigabatrin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each new prescription and refill of vigabatrin. Take exactly as directed. While using this medication, avoid alcohol and other prescription or OTC medications without consulting prescriber. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician of increased depression or thoughts of suicide or self harm. Wear identification of epileptic status and medications. Vigabatrin may cause permanent vision damage; report changes in vision, particularly peripheral vision, immediately. Abnormal MRI signal changes may occur with vigabatrin; the clinical significance of these changes are unknown. Report CNS changes, mentation changes, or changes in cognition; changes in gait; persistent GI symptoms (cramping, constipation, vomiting, anorexia); rash or skin irritations; worsening of seizure activity, or loss of seizure control. Do not discontinue abruptly (an increase in seizure activity may result).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1042225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vigabatrin is not effective in absence or febrile seizures; exacerbation of certain seizure types or onset of new types of seizures have been seen after initiation of vigabatrin.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bar-Oz B, Nulman I, Koren G, et al, &ldquo;Anticonvulsants and Breast-Feeding: A Critical Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(2):113-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/10937463/pubmed\" id=\"10937463\" target=\"_blank\">",
"        10937463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Camposano SE, Major P, Halpern E, et al, \"Vigabatrin in the Treatment of Childhood Epilepsy: A Retrospective Chart Review of Efficacy and Safety Profile,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2008, 49(7):1186-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/18479386/pubmed\" id=\"18479386\" target=\"_blank\">",
"        18479386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Challier JC, Rey E, Bintein T, et al, \"Passage of S(+) and R(-) Gamma-Vinyl-GABA Across the Human Isolated Perfused Placenta,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1992, 34(2):139-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/1419475/pubmed\" id=\"1419475\" target=\"_blank\">",
"        1419475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coppola G, \"Treatment of Partial Seizures in Childhood: An Overview,\"",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2004, 18(3):133-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/14871158/pubmed\" id=\"14871158\" target=\"_blank\">",
"        14871158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawthom C, Smith PE, and Wild JM, \"",
"      <i>",
"       In utero",
"      </i>",
"      Exposure to Vigabatrin: No Indication of Visual Field Loss,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2009, 50(2):318-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/18616557/pubmed\" id=\"18616557\" target=\"_blank\">",
"        18616557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mackay MT, Weiss SK, Adams-Webber T, et al, \"Practice Parameter: Medical Treatment of Infantile Spasms: Report of the American Academy of Neurology and the Child Neurology Society,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 62(10):1668-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/15159460/pubmed\" id=\"15159460\" target=\"_blank\">",
"        15159460",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearl PL, Vezina LG, Saneto RP, et al, \"Cerebral MRI Abnormalities Associated With Vigabatrin Therapy,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2009, 50(2):184-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/18783433/pubmed\" id=\"18783433\" target=\"_blank\">",
"        18783433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sorri I, Herrg&aring;rd E, Viinikainen K, et al, \"Ophthalmologic and Neurologic Findings in Two Children Exposed to Vigabatrin",
"      <i>",
"       in utero",
"      </i>",
"      ,\"",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 2005, 65(1-2):117-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/15941649/pubmed\" id=\"15941649\" target=\"_blank\">",
"        15941649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tran A, O'Mahoney T, Rey E, et al, \"Vigabatrin: Placental Transfer",
"      <i>",
"       in vivo",
"      </i>",
"      and Excretion Into Breast Milk of the Enantiomers,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1998, 45(4):409-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/9578192/pubmed\" id=\"9578192\" target=\"_blank\">",
"        9578192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheless JW, Carmant L, Bebin M, et al, \"Magnetic Resonance Imaging Abnormalities Associated With Vigabatrin in Patients With Epilepsy,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2009, 50(2):195-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/19054414/pubmed\" id=\"19054414\" target=\"_blank\">",
"        19054414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Willmore LJ, Abelson MB, Ben-Menachem E, et al, \"Vigabatrin: 2008 Update,\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2009, 50(2):163-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25015/abstract-text/19230067/pubmed\" id=\"19230067\" target=\"_blank\">",
"        19230067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13101 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25015=[""].join("\n");
var outline_f24_27_25015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238848\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107369\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234016\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042182\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042214\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233994\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233980\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234385\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104264\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042220\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042203\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042183\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8308547\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234058\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042189\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7407982\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042190\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300217\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233987\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042202\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233989\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234002\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042222\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837874\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042205\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7408004\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042207\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042223\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042225\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=related_link\">",
"      Vigabatrin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/38/614?source=related_link\">",
"      Vigabatrin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_27_25016="Pravastatin: Drug information";
var content_f24_27_25016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pravastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/21/37204?source=see_link\">",
"    see \"Pravastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/2/17447?source=see_link\">",
"    see \"Pravastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16054981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pravachol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Pravastatin&reg;;",
"     </li>",
"     <li>",
"      CO Pravastatin;",
"     </li>",
"     <li>",
"      Dom-Pravastatin;",
"     </li>",
"     <li>",
"      JAMP-Pravastatin;",
"     </li>",
"     <li>",
"      Mint-Pravastatin;",
"     </li>",
"     <li>",
"      Mylan-Pravastatin;",
"     </li>",
"     <li>",
"      Novo-Pravastatin;",
"     </li>",
"     <li>",
"      Nu-Pravastatin;",
"     </li>",
"     <li>",
"      PHL-Pravastatin;",
"     </li>",
"     <li>",
"      PMS-Pravastatin;",
"     </li>",
"     <li>",
"      Pravachol&reg;;",
"     </li>",
"     <li>",
"      RAN&trade;-Pravastatin;",
"     </li>",
"     <li>",
"      ratio-Pravastatin;",
"     </li>",
"     <li>",
"      Riva-Pravastatin;",
"     </li>",
"     <li>",
"      Sandoz-Pravastatin;",
"     </li>",
"     <li>",
"      Teva-Pravastatin;",
"     </li>",
"     <li>",
"      ZYM-Pravastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F212570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F212527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperlipidemias, primary prevention of coronary events, secondary prevention of cardiovascular events:",
"     </b>",
"     Oral: Initial: 40 mg once daily; titrate dosage to response (usual range: 10-80 mg) (maximum dose: 80 mg once daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment for pravastatin with concomitant medications:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Clarithromycin:",
"     </i>",
"     Limit daily pravastatin dose to 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cyclosporine:",
"     </i>",
"     Initial: 10 mg pravastatin daily, titrate with caution (maximum dose: 20 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F212550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/2/17447?source=see_link\">",
"      see \"Pravastatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heterozygous familial hypercholesterolemia (HeFH):",
"     </b>",
"     Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-13 years: 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment for pravastatin with concomitant medications (clarithromycin, cyclosporine):",
"      </i>",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F212528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F212529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Significant impairment: Initial dose: 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F212530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pravachol&reg;: 20 mg, 40 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F212500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F212499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with dietary therapy for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Primary prevention of coronary events: In hypercholesterolemic patients without established coronary heart disease to reduce cardiovascular morbidity (myocardial infarction, coronary revascularization procedures) and mortality.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Secondary prevention of cardiovascular events in patients with established coronary heart disease: To slow the progression of coronary atherosclerosis; to reduce cardiovascular morbidity (myocardial infarction, coronary vascular procedures) and to reduce mortality; to reduce the risk of stroke and transient ischemic attacks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hyperlipidemias: Reduce elevations in total cholesterol, LDL-C, apolipoprotein B, and triglycerides (elevations of 1 or more components are present in Fredrickson type IIa, IIb, III, and IV hyperlipidemias)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heterozygous familial hypercholesterolemia (HeFH): In pediatric patients, 8-18 years of age, with HeFH having LDL-C &ge;190 mg/dL",
"     <b>",
"      or",
"     </b>",
"     LDL &ge;160 mg/dL with positive family history of premature cardiovascular disease (CVD) or 2 or more CVD risk factors in the pediatric patient",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pravachol&reg; may be confused with atorvaSTATin, Prevacid&reg;, Prinivil&reg;, propranolol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pravastatin may be confused with nystatin, pitavastatin, prasugrel",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F212568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in short-term trials; safety and tolerability with long-term use were similar to placebo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 6%), fatigue (4%), dizziness (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (7%), diarrhea (6%), heartburn (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (&gt;3x normal on two occasions: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergy, amnesia (reversible), anaphylaxis, angioedema, cholestatic jaundice, cirrhosis, cognitive impairment (reversible), confusion (reversible), cranial nerve dysfunction, dermatomyositis, erythema multiforme, ESR increase, fulminant hepatic necrosis, gynecomastia, hemolytic anemia, hepatitis, hepatoma, lens opacity, libido change, lupus erythematosus-like syndrome, memory disturbance (reversible), memory impairment (reversible), muscle weakness, myopathy, neuropathy, pancreatitis, paresthesia, peripheral nerve palsy, polymyalgia rheumatica, positive ANA, purpura, rhabdomyolysis, Stevens-Johnson syndrome, taste disturbance, tremor, vasculitis, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional class-related events or case reports (not necessarily reported with pravastatin therapy): Angioedema, blood glucose increased, cataracts, depression, diabetes mellitus (new onset), dyspnea, eosinophilia, erectile dysfunction, facial paresis, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, hypersensitivity reaction, immune-mediated necrotizing myopathy (IMNM), impaired extraocular muscle movement, impotence, interstitial lung disease, leukopenia, malaise, memory loss, ophthalmoplegia, paresthesia, peripheral neuropathy, photosensitivity, psychic disturbance, skin discoloration, thrombocytopenia, thyroid dysfunction, toxic epidermal necrolysis, transaminases increased, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F212503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pravastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F212485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy.  If an alternate etiology is not identified, do not restart pravastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of other drugs which may cause rhabdomyolysis (including colchicine, gemfibrozil, fibric acid derivatives, or niacin at doses &ge;1 g/day). Discontinue in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated in patients with active liver disease or unexplained transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of pravastatin with some drugs may require cautious use or may require dosage adjustments (see Drug Interactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special Populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age, these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Treatment is not recommended in patients &lt;8 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Liver function tests: Must be monitored by periodic laboratory assessment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F212564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein, SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Pravastatin. Management: Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic). Management: Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Pravastatin. This effect has only been demonstrated with darunavir/ritonavir. The individual contributions of darunavir and ritonavir are unknown.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Pravastatin. Gemfibrozil may increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Pravastatin may enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May decrease the serum concentration of Pravastatin. This effect has only been demonstrated with saquinavir/ritonavir. The individual contributions of saquinavir and ritonavir are unknown.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F212518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Consumption of large amounts of ethanol may increase the risk of liver damage with HMG-CoA reductase inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease pravastatin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F212506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F212534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F212507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy.  Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F212505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pravachol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $392.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $576.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (90): $576.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pravastatin Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $289.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $294.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $431.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (90): $431.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F212494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed at intervals of 4 weeks or more.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F212508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Astin (MX);",
"     </li>",
"     <li>",
"      Brakhor (MX);",
"     </li>",
"     <li>",
"      Bristacol (ES);",
"     </li>",
"     <li>",
"      Brufincol (MX);",
"     </li>",
"     <li>",
"      Cholespar (ID);",
"     </li>",
"     <li>",
"      Cholstat (AU);",
"     </li>",
"     <li>",
"      Col-Alphar (MX);",
"     </li>",
"     <li>",
"      Colpradin (MX);",
"     </li>",
"     <li>",
"      Elisor (FR);",
"     </li>",
"     <li>",
"      Emipastin (MX);",
"     </li>",
"     <li>",
"      Genoestatina (MX);",
"     </li>",
"     <li>",
"      Kenstatin (MX);",
"     </li>",
"     <li>",
"      Koloskol (ID);",
"     </li>",
"     <li>",
"      Lipemol (ES);",
"     </li>",
"     <li>",
"      Liplat (ES);",
"     </li>",
"     <li>",
"      Lipostat (AU, BG, CZ, EE, GB, HN, HU, IE, PL);",
"     </li>",
"     <li>",
"      Liprachol (AU);",
"     </li>",
"     <li>",
"      Liprevil (DE);",
"     </li>",
"     <li>",
"      Loretsin (MX);",
"     </li>",
"     <li>",
"      Mechol (TW);",
"     </li>",
"     <li>",
"      Mevalotin (CL, DE, ID, JP, KP);",
"     </li>",
"     <li>",
"      Mevalotin Protect (TH);",
"     </li>",
"     <li>",
"      Novales (ID);",
"     </li>",
"     <li>",
"      Novina (MX);",
"     </li>",
"     <li>",
"      Prastan (KP);",
"     </li>",
"     <li>",
"      Pratin (MY, TW);",
"     </li>",
"     <li>",
"      Prava (ZA);",
"     </li>",
"     <li>",
"      Pravachol (AT, AU, BB, BM, BS, BZ, DK, FI, GR, GY, HK, JM, NO, NZ, PE, PK, SE, SR, TR, TT, VE);",
"     </li>",
"     <li>",
"      Pravacol (AR, BR, CN, EC, MX, PE, PT);",
"     </li>",
"     <li>",
"      Pravalip (IL);",
"     </li>",
"     <li>",
"      Pravaselect (IT);",
"     </li>",
"     <li>",
"      Pravasin (DE, LU);",
"     </li>",
"     <li>",
"      Pravasine (BE);",
"     </li>",
"     <li>",
"      Pravator (IN);",
"     </li>",
"     <li>",
"      Pravaz (PH);",
"     </li>",
"     <li>",
"      Pravyl (CO);",
"     </li>",
"     <li>",
"      Pu Hui Zhi (CL);",
"     </li>",
"     <li>",
"      Sanaprav (AT, IT);",
"     </li>",
"     <li>",
"      Selectin (IT);",
"     </li>",
"     <li>",
"      Selektine (NL);",
"     </li>",
"     <li>",
"      Selipran (AT, CH);",
"     </li>",
"     <li>",
"      Tissulest (MX);",
"     </li>",
"     <li>",
"      Vasten (FR);",
"     </li>",
"     <li>",
"      Vastoran (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F212484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pravastatin is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is the rate-limiting enzyme involved in",
"     <i>",
"      de novo",
"     </i>",
"     cholesterol synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F212502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Several days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapidly absorbed; average absorption 34%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic multiple metabolites; primary metabolite is 3&alpha;-hydroxy-iso-pravastatin (2.5% to 10% activity of parent drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 77 hours (including all metabolites); pravastatin: &sim;2-3 hours (Pan, 1990); 3&alpha;-hydroxy-iso-pravastatin: ~1.5 hours (Gustavson, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (70%); urine (&le;20%, 8% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dupuis J, Tardif JC, Cernacek P, et al, &ldquo;Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(25):3227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/10385495/pubmed\" id=\"10385495\" target=\"_blank\">",
"        10385495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134(4):824-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/18689579/pubmed\" id=\"18689579\" target=\"_blank\">",
"        18689579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/11136683/pubmed\" id=\"11136683\" target=\"_blank\">",
"        11136683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gustavson LE, Schweitzer SM, Koehne-Voss S, et al, \"The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3-Alpha-Hydroxy Isomeric Metabolite,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2005, 45(8):947-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/16027406/pubmed\" id=\"16027406\" target=\"_blank\">",
"        16027406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren MJ, Smith DG, Hunninghake DB, et al, &ldquo;The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients. A Comparison of Atorvastatin, Simvastatin, Lovastatin and Fluvastatin,&rdquo;",
"      <i>",
"       Pharmacoeconomics",
"      </i>",
"      , 1998, 14(1):59-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/10182195/pubmed\" id=\"10182195\" target=\"_blank\">",
"        10182195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis SJ, Moye LA, Sacks FM, et al, &ldquo;Effect of Pravastatin on Cardiovascular Events in Older Patients With Myocardial Infarction and Cholesterol Levels in the Average Range. Results of the Cholesterol and Recurrent Events (CARE) Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1998, 129(9):681-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/9841599/pubmed\" id=\"9841599\" target=\"_blank\">",
"        9841599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pan HY, DeVault AR, Swites BJ, et al, \"Pharmacokinetics and Pharmacodynamics of Pravastatin Alone and With Cholestyramine in Hypercholesterolemia,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1990, 48(2):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/2116260/pubmed\" id=\"2116260\" target=\"_blank\">",
"        2116260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(3):499-511.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/12551878/pubmed\" id=\"12551878\" target=\"_blank\">",
"        12551878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips BG, Yim JM, Brown EJ Jr, et al, &ldquo;Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1996, 131(5):872-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/8615304/pubmed\" id=\"8615304\" target=\"_blank\">",
"        8615304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Prevention of Cardiovascular Events and Death With Pravastatin in Patients With Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(19):1349-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/9841303/pubmed\" id=\"9841303\" target=\"_blank\">",
"        9841303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacks FM, Pfeffer MA, Moye LA, et al, &ldquo;The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels. Cholesterol and Recurrent Events Trial Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(14):1001-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/8801446/pubmed\" id=\"8801446\" target=\"_blank\">",
"        8801446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White HD, Simes RJ, Anderson NE, et al, &ldquo;Pravastatin Therapy and the Risk of Stroke,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(5):317-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25016/abstract-text/10922421/pubmed\" id=\"10922421\" target=\"_blank\">",
"        10922421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9804 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25016=[""].join("\n");
var outline_f24_27_25016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16054981\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212570\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212527\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212550\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212528\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212529\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212530\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212496\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212481\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212500\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212499\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212578\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212568\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212503\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212485\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212564\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212490\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212518\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212492\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212506\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212534\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212507\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212505\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212494\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212508\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212484\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212502\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/21/37204?source=related_link\">",
"      Pravastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/2/17447?source=related_link\">",
"      Pravastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_27_25017="Ethinyl estradiol and etonogestrel: Drug information";
var content_f24_27_25017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and etonogestrel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/39/37494?source=see_link\">",
"    see \"Ethinyl estradiol and etonogestrel: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NuvaRing&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      NuvaRing&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F169230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F169215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Vaginal: One ring, inserted vaginally and left in place for 3 consecutive weeks, then removed for 1 week. A new ring is inserted 7 days after the last was removed (even if bleeding is not complete) and should be inserted at approximately the same time of day the ring was removed the previous week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Initial treatment should begin as follows (pregnancy should always be ruled out first):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     No hormonal contraceptive use in the past month: Insert ring on the first day of menstrual cycle (&ldquo;Day 1&rdquo;). May also insert on days 2-5 even if bleeding is not complete, however,",
"     <b>",
"      a spermicide or barrier method of contraception should be used for the following 7 days.",
"     </b>",
"     *",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Switching from combination oral contraceptive: Ring can be inserted on any day within 7 days after the last",
"     <b>",
"      active",
"     </b>",
"     tablet in the cycle was taken and no later than the first day a new cycle of tablets would begin. Additional forms of contraception are not needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Switching from progestin-only contraceptive:",
"     <b>",
"      A spermicide or barrier method of contraception should be used for the following 7 days with any of the following.",
"     </b>",
"     *",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If previously using a progestin-only mini-pill, insert the ring on any day of the month; do not skip days between the last pill and insertion of the ring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If previously using an implant, insert the ring on the same day of implant removal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If previously using a progestin-containing IUD, insert the ring on day of IUD removal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If previously using a progestin injection, insert the ring on the day the next injection would be given.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Following complete 1st trimester abortion: Insert ring within the first 5 days of abortion. If not inserted within 5 days, follow instructions for &ldquo;No hormonal contraceptive use within the past month&rdquo; and instruct patient to use a nonhormonal contraceptive in the interim.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Following delivery or 2nd trimester abortion: Insert ring 4 weeks postpartum (in women who are not breast-feeding) or following 2nd trimester abortion.",
"     <b>",
"      A spermicide or barrier method of contraception should be used for the following 7 days.",
"     </b>",
"     *",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If the ring is accidentally removed from the vagina at anytime during the 3-week period of use, it may be rinsed with cool or lukewarm water (not hot) and reinserted as soon as possible. If the ring is not reinserted within 3 hours, contraceptive effectiveness will be decreased.",
"     <b>",
"      A spermicide or barrier method of contraception should be used until the ring has been in place for 7 consecutive days.",
"     </b>",
"     *",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If the ring has been removed for longer than 1 week, pregnancy must be ruled out prior to restarting therapy.",
"     <b>",
"      A spermicide or barrier method of contraception should be used for the following 7 days.",
"     </b>",
"     *",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If the ring has been left in place for &gt;3 weeks, a new ring should be inserted following a 1-week (ring-free) interval. Protection continues during week 4, however, if the ring is left in place &gt;4 weeks, pregnancy must be ruled out prior to insertion and",
"     <b>",
"      a spermicide or barrier method of contraception should be used for the following 7 days.",
"     </b>",
"     *",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disconnected ring: In the event the ring disconnects at the weld joint, discard and replace with a new ring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     *",
"     <b>",
"      Note:",
"     </b>",
"     Diaphragms may interfere with proper ring placement, and therefore, are not recommended for use as an additional form of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F169224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Contraception: Vaginal: Refer to adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F169216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F169217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ring, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     NuvaRing&reg;: Ethinyl estradiol 0.015 mg/day and etonogestrel 0.12 mg/day (3s) [3-week duration]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F169192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vaginal: Wash hands and remove ring from protective pouch (keep pouch for later ring disposal). Press sides of ring together between thumb and index finger and insert folded ring into vagina. Specific placement is not required for ring to be effective, but ring should be inserted far enough into the vagina as to be comfortable. To remove, hook index finger around rim and pull out. Vaginal ring",
"     <b>",
"      cannot",
"     </b>",
"     be disposed of in the toilet. New rings should be inserted at approximately the same time of day the ring was removed the previous week. If the ring accidentally falls out, it may be rinsed with cool or warm (not hot) water and replaced. However, it must be replaced within 3 hours. Refer to dosing if ring is out of place for &gt;3 hours. Tampons do not interfere with the effectiveness of the ring; caution should be used when removing tampon not to remove ring. The ring may interfere with correct placement of diaphragms; diaphragms should not be used as a back-up method of contraception. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F169191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F169227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis; dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F169228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The most common adverse reactions associated with NuvaRing&reg; (5% to 14%): Headache, nausea, sinusitis, upper respiratory tract infection, vaginal secretion, vaginitis, and weight gain. The following reactions have been associated with combination hormonal contraceptive use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Increased risk or evidence of association with use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI, venous thrombosis (with or without embolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gallbladder disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic adenomas, liver tumors (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions considered drug related:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, varicose vein aggravation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, migraine, mood changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Chloasma, melasma, rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast changes (enlargement, pain, secretion, tenderness), fluid retention, infertility (temporary), lactation decreased (with use immediately postpartum), menstrual flow changes, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal cramps, abdominal pain, appetite changes, nausea, weight changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cervical ectropion, cervical secretion, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Folate decreased, porphyria exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature changes (steepening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions (including angioedema, circulatory collapse, respiratory collapse, urticaria), SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions in which association is not confirmed or denied:",
"     </i>",
"     Acne, Budd-Chiari syndrome, cataracts, colitis, cystitis-like syndrome, dizziness, dysmenorrhea, erythema multiforme, erythema nodosum, headache, hemolytic uremic syndrome, hemorrhagic eruption, hirsutism, libido changes, nervousness, optic neuritis (with or without partial or complete loss of vision), pancreatitis, premenstrual syndrome, renal function impaired, scalp hair loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F169195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethinyl estradiol, etonogestrel, or any component of the formulation; breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding, cholestatic jaundice of pregnancy, jaundice with prior combination hormonal contraceptive use",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), headaches with focal neurological symptoms, hypertension (uncontrolled), valvular heart disease with thrombogenic complications, women &gt;35 years of age who smoke, major surgery with prolonged immobilization.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F169180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with (or history of) breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may effect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: May increase the risk of thromboembolism; discontinue use of combination hormonal contraceptives if an arterial or venous thrombotic event occurs. Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Presentation of irregular, unresolving vaginal bleeding warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Use is contraindicated in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal preparation: Vaginally-administered combination hormonal contraceptive agents may have a similar adverse effects associated with oral contraceptive products. In order to reduce some of the possible risks, the minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used. May not be appropriate for use in women with conditions that make the vagina susceptible to irritation or ulceration. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F169225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May diminish the therapeutic effect of Etonogestrel. Management: Use a reliable barrier contraceptive if efavirenz is used in combination with etonogestrel.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F169208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives, when inadvertently used early in pregnancy, have not been associated with teratogenic effects. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch. In a study using the vaginal ring, ethinyl estradiol serum concentrations were decreased in obese women (BMI 30-39.9 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; n=19) in comparison to women of normal weight (BMI 19-24.9 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; n=18; p= 0.004); etonogestrel concentrations did not differ significantly. Bleeding and spotting were more frequent in the obese women. The study was not powered to evaluate contraceptive effectiveness (Westhoff, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC, 2011). The manufacturer states that combination hormonal contraceptives should not be started until &ge;4 weeks after delivery in women who choose not to breastfeed, or &ge;4 weeks after a second trimester abortion or miscarriage.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F169219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F169199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; alternative form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F169197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ring",
"     </b>",
"     (NuvaRing Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12-0.015 mg/24 hrs (1): $99.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F169188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. In patients with persistent urinary symptoms, assess for inadvertent urinary bladder insertion if ring is not otherwise located.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F855131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      NuvaRing (AT, AU, BE, BR, CH, CN, CO, CR, CZ, DE, DK, DO, EE, FI, FR, GB, GR, GT, HN, IE, IL, IT, KP, MX, MY, NI, NL, NO, NZ, PA, PE, PL, PT, RU, SE, SG, SV, TH, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F169179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination hormonal contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F169194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Serum levels (contraceptive effectiveness) decrease after 3 weeks of continuous use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Ethinyl estradiol and etonogestrel: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tampons do not interfere with absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ethinyl estradiol: 98%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Etonogestrel: 32% to sex hormone-binding globulin (SHBG) and 66% to albumin; SHBG capacity is affected by plasma ethinyl estradiol levels",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ethinyl estradiol: Hepatic via CYP3A4; forms metabolites (weak estrogenic activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Etonogestrel: Hepatic via CYP3A4; forms metabolites (activity not known)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Vaginal: Ethinyl estradiol: ~56% Etonogestrel: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Ethinyl estradiol: 45 hours; Etonogestrel: 29 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Vaginal: Ethinyl estradiol: 60 hours; Etonogestrel: 200 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Ethinyl estradiol and etonogestrel: Urine, bile, and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenfield GM and Griffin JM, &ldquo;Clinical Pharmacokinetics of Contraceptive Steroids. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 20(1):15-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/2029800/pubmed\" id=\"2029800\" target=\"_blank\">",
"        2029800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westhoff CL, Torgal AH, Mayeda ER, et al, \"Pharmacokinetics and Ovarian Suppression During Use of a Contraceptive Vaginal Ring in Normal-Weight and Obese Women,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2012, 207(1):39.e1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/27/25017/abstract-text/22727346/pubmed\" id=\"22727346\" target=\"_blank\">",
"        22727346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8684 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25017=[""].join("\n");
var outline_f24_27_25017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708762\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855130\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169230\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169215\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169224\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169216\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169217\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169190\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169176\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169192\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169191\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169227\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169228\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169195\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169180\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169225\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169184\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169208\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169186\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169198\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169219\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169199\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169197\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169188\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855131\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169179\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169194\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8684|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/39/37494?source=related_link\">",
"      Ethinyl estradiol and etonogestrel: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_27_25018="Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension";
var content_f24_27_25018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/27/25018/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/27/25018/contributors\">",
"     Brent M Egan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/27/25018/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/27/25018/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/27/25018/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/27/25018/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/27/25018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/27/25018/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/27/25018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a common problem in elderly persons (age greater than 60 to 65 years), reaching a prevalence as high as 60 to 80 percent (",
"    <a class=\"graphic graphic_figure graphicRef81756 graphicRef58221 \" href=\"UTD.htm?1/63/2032\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In the United States, for example, hypertension was observed in 67 percent of adults aged 60 and older who were participants in the National Health and Nutrition Examination Survey (NHANES) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related issue is the risk of developing hypertension over time in an elderly person who is normotensive. This issue was addressed in two reports from the Framingham Heart Study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study examined the incidence of hypertension (defined as blood pressure greater than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg or use of antihypertensive drug) over a four-year period among individuals who initially had optimal (less than",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg), normal (120 to",
"      <span class=\"nowrap\">",
"       129/80",
"      </span>",
"      to 84 mmHg) or high-normal (130 to",
"      <span class=\"nowrap\">",
"       139/85",
"      </span>",
"      to 89 mmHg) blood pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/5\">",
"       5",
"      </a>",
"      ]. There was a progressive increase in the frequency of development of hypertension in patients over age 65 (16, 26, and 50 percent in the optimal, normal, and high-normal groups, respectively). Similar findings were noted in younger individuals, but the rates of progression were lower.",
"     </li>",
"     <li>",
"      The second report estimated that individuals aged 55 to 65 who do not have hypertension have a",
"      <strong>",
"       90 percent",
"      </strong>",
"      lifetime risk of developing stage 1 hypertension (blood pressure 140 to",
"      <span class=\"nowrap\">",
"       159/90",
"      </span>",
"      to 99 mmHg) and a",
"      <strong>",
"       40 percent",
"      </strong>",
"      lifetime risk of developing stage 2 hypertension (blood pressure",
"      <span class=\"nowrap\">",
"       &ge;160/&ge;100",
"      </span>",
"      mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149558066\">",
"    <span class=\"h1\">",
"     HYPERTENSION AWARENESS AND CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from the National Health and Nutrition Examination survey (NHANES) evaluated the trends in hypertension prevalence, awareness, treatment and control of hypertension in the United States from 1988 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/4\">",
"     4",
"    </a>",
"    ]. The overall results from this analysis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4755?source=see_link\">",
"     \"The prevalence and control of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23828?source=see_link&amp;anchor=H1#H1\">",
"     \"Patient adherence and the treatment of hypertension\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to the characteristics in hypertensive older patients (60 years of age or more) compared with younger patients (18 to 39 years of age in 2007 to 2008), older patients were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More likely to be aware of their hypertension (84 versus 66 percent).",
"     </li>",
"     <li>",
"      More likely to be treated (80 versus 50 percent).",
"     </li>",
"     <li>",
"      Once treated, less likely to achieve blood pressure control (64 versus 82 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increases in awareness and treatment may reflect at least in part more frequent doctor visits in elderly patients for comorbid disease. The lower rate of blood pressure control may at least in part reflect the increased risk of resistant hypertension in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/7\">",
"     7",
"    </a>",
"    ]. Therapeutic inertia (ie, failure to intensify the treatment regimen when blood pressure goals are unmet) may also contribute to lower rates of hypertension control in older patients. (See",
"    <a class=\"local\" href=\"#H154681896\">",
"     'Uncontrolled hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISOLATED SYSTOLIC HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated systolic hypertension (ISH) has generally been defined as a systolic blood pressure above 160 mmHg, with a diastolic blood pressure below 90 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, as used in the seventh Joint National Committee report [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/11\">",
"     11",
"    </a>",
"    ] and supported by other experts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], a systolic blood pressure of 140 mmHg is the upper limit of normal at all ages.",
"   </p>",
"   <p>",
"    ISH mostly occurs in older patients. Data from the Framingham Heart Study and the National Health and Nutrition Examination Survey have shown that the systolic pressure rises and the diastolic pressure falls after age 60 in both normotensive and untreated hypertensive subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/14\">",
"     14",
"    </a>",
"    ] and that ISH accounts for 60 to 80 percent of cases of hypertension in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. Furthermore, the systolic and pulse pressures appear to be the major predictors of coronary disease in the elderly; in contrast, diastolic pressure is the major predictor under age 50 and all three indices were equal predictors between the ages of 50 and 59 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The elevation in pulse pressure in patients with ISH is primarily due to diminished arterial compliance. ISH may also result from an increase in cardiac output due to anemia, hyperthyroidism, aortic insufficiency, arteriovenous fistula, or Paget disease of bone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ISH is associated with a two- to fourfold increase in the risk of myocardial infarction, left ventricular hypertrophy, renal dysfunction, stroke, and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. Even in patients who also have diastolic hypertension, the cardiovascular risk correlates more closely with the systolic than the diastolic blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Importance of diastolic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among elderly patients, coronary heart disease risk varies directly with the systolic and pulse pressures and inversely with the diastolic pressure (ie, lower diastolic pressures are associated with increased risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/8,16,20,21\">",
"     8,16,20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative importance of the systolic, diastolic, and pulse pressures is different in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/16,20\">",
"     16,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypertension: Who should be treated?\", section on 'What level of BP increases risk?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26823?source=see_link\">",
"     \"Increased pulse pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the observations concerning worse outcomes in elderly patients with lower diastolic pressures primarily came from population studies or from baseline blood pressures in clinical trials, not after treatment in clinical trials. In the SHEP trial, for example, the mean baseline blood pressure was",
"    <span class=\"nowrap\">",
"     170/77",
"    </span>",
"    mmHg and the attained blood pressure was",
"    <span class=\"nowrap\">",
"     143/68",
"    </span>",
"    mmHg in the treated group and",
"    <span class=\"nowrap\">",
"     155/72",
"    </span>",
"    in the placebo group; the mean age was 72 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/22\">",
"     22",
"    </a>",
"    ]. Despite the low attained diastolic pressure, the treated group had significantly better outcomes. A similar mean systolic blood pressure and higher diastolic blood pressure",
"    <span class=\"nowrap\">",
"     (143/78",
"    </span>",
"    mmHg) were attained in the treated group in the HYVET trial of the very old (mean age 84) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'SHEP trial'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'HYVET trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When treating elderly patients with isolated systolic hypertension, there are no clear data that provide guidance related to the minimum diastolic blood pressure that can be tolerated. An analysis from the SHEP trial found significant increases in cardiovascular events in the active treatment group when the diastolic blood pressure was &le;60 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/24\">",
"     24",
"    </a>",
"    ]. In other reports of treated patients, an increase in risk of stroke began at diastolic pressures below 65 mmHg in a report from the observational Rotterdam study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/25\">",
"     25",
"    </a>",
"    ] and, in the INVEST trial of hypertensive patients with coronary artery disease who were randomly assigned to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    based strategy, an increased risk of myocardial infarction that began at diastolic pressures between 61 and 70 mmHg and increased approximately 2.5-fold further at diastolic pressures &le;60 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations do not prove a cause-and-effect relationship between lower diastolic pressures and adverse outcomes. In a meta-analysis that included two trials of isolated systolic hypertension, a J-shaped curve for mortality was noted with both systolic pressure (",
"    <a class=\"graphic graphic_figure graphicRef80901 \" href=\"UTD.htm?34/58/35759\">",
"     figure 2",
"    </a>",
"    ) and diastolic pressure (",
"    <a class=\"graphic graphic_figure graphicRef73430 \" href=\"UTD.htm?18/38/19055\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/27\">",
"     27",
"    </a>",
"    ]. However, a J-curve was seen in treated and untreated patients and was not specific for cardiovascular mortality. The authors concluded that the J-curve is probably explained by poor health associated with lower blood pressures, not an adverse effect of antihypertensive therapy.",
"   </p>",
"   <p>",
"    In summary, although adverse outcomes that can be ascribed only to excessive blood pressure lowering with antihypertensive drugs are probably not common in patients with isolated systolic hypertension, cardiovascular events can occur if the diastolic pressure is reduced below the level needed to maintain perfusion to vital organs, particularly the heart. We suggest a minimum posttreatment diastolic pressure of 60 mmHg overall or 65 mmHg in patients with known coronary artery disease unless symptoms that could be attributable to hypoperfusion occur at higher pressures (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Goal blood pressure'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hypertension in all patients, independent of age, consists of lifestyle modifications and antihypertensive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lifestyle modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in younger patients, lifestyle modifications (eg, dietary salt restriction, weight loss in obese patients) can lower the blood pressure in elderly patients with hypertension. In particular, dietary sodium intake should be moderately restricted to 100 to 120",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    (2300 to 2800",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    since the pressor effect of sodium excess and the antihypertensive efficacy of sodium restriction progressively increase with age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of hypertension in adults\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"     \"Diet in the treatment and prevention of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     TONE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of salt restriction and weight loss in hypertensive elderly patients was demonstrated in the TONE trial of 975 older persons (aged 60 to 80) who had a blood pressure",
"    <span class=\"nowrap\">",
"     &lt;145/&lt;85",
"    </span>",
"    mmHg on one antihypertensive drug; 585 were obese [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/29\">",
"     29",
"    </a>",
"    ]. The patients were randomly assigned to usual care or to salt restriction, weight loss (in obese patients), or both. Those assigned to salt restriction had a 40",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    decrease in sodium excretion while, in obese patients, a regimen of diminished caloric intake and increased physical activity was associated with a persistent weight loss of 4.7 kg; these parameters were unchanged in the usual care group. After three months of intervention, withdrawal of the antihypertensive drug was attempted.",
"   </p>",
"   <p>",
"    The primary end point was a diagnosis of high blood pressure at one or more follow-up visits, treatment with antihypertensive drugs, or a cardiovascular event. The reduction in blood pressure compared with usual care were",
"    <span class=\"nowrap\">",
"     2.6/1.1",
"    </span>",
"    mmHg with salt restriction,",
"    <span class=\"nowrap\">",
"     3.2/0.3",
"    </span>",
"    mmHg with weight loss, and",
"    <span class=\"nowrap\">",
"     4.5/2.6",
"    </span>",
"    mmHg with combined therapy. The primary end point at 30 months occurred significantly less often with salt restriction (62 versus 76 percent with usual care), weight reduction in obese subjects (61 versus 74 percent), and combined salt restriction and weight reduction in obese subjects (56 versus 84 percent).",
"   </p>",
"   <p>",
"    Older patients may have difficulty complying with dietary salt restriction for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They may ingest more salt to compensate for a decrease in taste sensitivity.",
"     </li>",
"     <li>",
"      They may depend more on processed, prepackaged foods that are high in sodium rather than fresh foods that are low in sodium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trials of antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have provided clear evidence of benefit from treating hypertension in elderly patients, including those over the age of 80 (",
"    <a class=\"graphic graphic_table graphicRef83927 \" href=\"UTD.htm?7/23/7548\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/8,22,23,30-33\">",
"     8,22,23,30-33",
"    </a>",
"    ]. Most of these trials involved patients with isolated systolic hypertension, but some had diastolic hypertension. In addition, trials of patients with diastolic hypertension included some elderly patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2000 meta-analysis included eight outcome trials of 15,693 patients &ge;60 years of age with isolated systolic hypertension (including SHEP, Syst-Eur, and MRC described below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/8\">",
"     8",
"    </a>",
"    ]. At a median follow-up of 3.8 years, the number of patients who needed to be treated for five years to prevent one major cardiovascular event was 26. The number needed to be treated was lower in men (18 versus 38 in women [percent of patients benefitting 5.6 and 2.6 percent, respectively]), patients aged 70 or more (19 versus 39 in patients under age 70 [percent of patients benefitting 5.3 and 2.6 percent, respectively]), and those with previous cardiovascular events (16 versus 37 without such a history [percent of patients benefitting 6.3 and 2.6 percent, respectively]).",
"   </p>",
"   <p>",
"    Total mortality correlated directly with systolic blood pressure at study entry, but inversely with diastolic blood pressure. However, the diastolic blood pressure was not significantly associated with outcome for combined fatal and nonfatal events.",
"   </p>",
"   <p>",
"    These results underestimate the true benefit of effectively treating versus not treating isolated systolic hypertension, as illustrated by the following findings in the SHEP trial described in the next section [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/22\">",
"     22",
"    </a>",
"    ]. Only about 70 percent of treated patients reached goal blood pressure during the study, yet the outcomes of the nonresponders were included in the analysis. In addition, increases in blood pressure necessitated the institution of antihypertensive medications in 13 percent of placebo-treated patients at one year and 44 percent at five years.",
"   </p>",
"   <p>",
"    The trials in the meta-analysis all had baseline mean systolic pressures of 160 mmHg or more [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/8\">",
"     8",
"    </a>",
"    ]. No trials have been performed in patients with isolated systolic hypertension with baseline systolic pressure of 140 to 159 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/34\">",
"     34",
"    </a>",
"    ]. The recommendation to treat such patients is based upon observational studies that show a graded relationship between increasing systolic blood pressure and cardiovascular risk (",
"    <a class=\"graphic graphic_figure graphicRef57839 graphicRef60876 \" href=\"UTD.htm?41/19/42297\">",
"     figure 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypertension: Who should be treated?\", section on 'What level of BP increases risk?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     SHEP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Systolic Hypertension in the Elderly Program (SHEP) trial included 4376 elderly patients (mean age 72) with a mean blood pressure of",
"    <span class=\"nowrap\">",
"     170/77",
"    </span>",
"    mmHg at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients were randomly assigned to antihypertensive therapy or placebo; the aim of therapy was at least a 20 mmHg reduction in systolic pressure to a level below 160 mmHg. Treatment began with 12.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    , which was then increased to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if necessary. Almost one-half of patients reached goal pressure solely with low-dose chlorthalidone.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     Atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    was added if a further antihypertensive response was required.",
"   </p>",
"   <p>",
"    The attained blood pressures were",
"    <span class=\"nowrap\">",
"     143/68",
"    </span>",
"    mmHg with active therapy and",
"    <span class=\"nowrap\">",
"     155/72",
"    </span>",
"    mmHg with placebo. Despite the potential risk of the relatively low diastolic pressures, the incidence of stroke at four to five years was significantly lower in treated patients (5.5 versus 8.2 percent with placebo) (",
"    <a class=\"graphic graphic_figure graphicRef58205 \" href=\"UTD.htm?20/24/20877\">",
"     figure 5",
"    </a>",
"    ). A similar one-third to one-quarter reduction was noted in the incidence of cardiac events, although this trend was not quite statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/35\">",
"     35",
"    </a>",
"    ]. These benefits were noted in both men and women and in all age groups, including patients over the age of 80, who were the focus of the HYVET trial. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'HYVET trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Further analyses demonstrated that active therapy was associated with a reduction in left ventricular mass index (-13 versus +6 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/36\">",
"     36",
"    </a>",
"    ] and that the reduction in cardiovascular events was not seen in the 7.2 percent of patients who developed hypokalemia (serum potassium less than 3.5",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Syst-Eur trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Syst-Eur trial randomly assigned 4695 patients over age 59 (mean age 70 years) with isolated systolic hypertension (mean initial sitting blood pressure of",
"    <span class=\"nowrap\">",
"     174/86",
"    </span>",
"    mmHg) to therapy with placebo or nitrendipine plus, if necessary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/31\">",
"     31",
"    </a>",
"    ]. The fall in blood pressure was greater with active therapy",
"    <span class=\"nowrap\">",
"     (23/7",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     13/2",
"    </span>",
"    mmHg).",
"   </p>",
"   <p>",
"    At four years, significant reductions were noted in stroke (7.9 versus 13.7 total end points per 1000 patient years), and fatal and nonfatal cardiac end points. It was estimated that treatment of 1000 patients for five years would prevent 53 cardiovascular endpoints and 29 strokes. Subgroup analysis found that the mortality benefit increased significantly with a higher systolic blood pressure at study entry, fell with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/38\">",
"     38",
"    </a>",
"    ], and was more pronounced in patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a subset of Syst-Eur, the vascular dementia project of over 2400 patients, antihypertensive therapy significantly lower the incidence of dementia compared to placebo (3.8 versus 7.7 cases per 1000 patient-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/40\">",
"     40",
"    </a>",
"    ]. It was estimated that treatment of 1000 patients for five years would prevent 19 cases of dementia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     MRC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Medical Research Council (MRC) trial included 3496 elderly patients (age 65 to 74 years) with systolic hypertension with or without diastolic hypertension (mean blood pressure",
"    <span class=\"nowrap\">",
"     185/91",
"    </span>",
"    mmHg) who were randomly assigned to one of three regimens:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ; or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/41\">",
"     41",
"    </a>",
"    ]. The patients were followed for a mean of 5.8 years. Compared to placebo, both treatment groups had a similar reduction in diastolic pressure. The reduction in systolic pressure was less in the atenolol group for the first two years, but not thereafter due at least in part to a higher rate of receiving supplemental antihypertensive drugs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     Hydrochlorothiazide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    significantly reduced the incidence of stroke, coronary events, and all cardiovascular events by 31, 44, and 35 percent, respectively. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    did not produce significant reductions in these end points. Similar findings have been noted in other trials in which beta blockers were associated with worse cardiovascular outcomes than other antihypertensive drugs, an effect that was primarily limited to patients over age 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H18#H18\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'Beta blockers as initial therapy?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     HYVET trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of treating hypertension in very old patients was directly addressed in the HYVET trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/23\">",
"     23",
"    </a>",
"    ]. In HYVET, 3845 patients who were at least 80 years of age (mean age 84) and had a sustained systolic blood pressure of at least 160 mmHg (mean",
"    <span class=\"nowrap\">",
"     173/91",
"    </span>",
"    mmHg) were randomly assigned to placebo or the thiazide diuretic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35846?source=see_link\">",
"     indapamide",
"    </a>",
"    . The angiotensin converting enzyme inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    or matching placebo was added in individuals who failed to meet the target blood pressure of",
"    <span class=\"nowrap\">",
"     150/80",
"    </span>",
"    mmHg. At two years, the mean blood pressure was",
"    <span class=\"nowrap\">",
"     15.0/6.1",
"    </span>",
"    mmHg lower with active therapy (approximately",
"    <span class=\"nowrap\">",
"     143/78",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     158/84",
"    </span>",
"    mmHg)",
"   </p>",
"   <p>",
"    The primary end point was fatal or nonfatal stroke. At two years, active therapy was associated with a significant reduction in fatal stroke (6.5 versus 10.7 percent) and an almost significant reduction in all strokes (12.4 versus 17.7 percent, p&lt;0.06). Death from all causes was reduced from 59.6 per 1000 persons per year in the placebo group to 47.2 per 1000 persons per year in the active treatment group.",
"   </p>",
"   <p>",
"    The authors suggested that the results of HYVET support a target blood pressure of less than",
"    <span class=\"nowrap\">",
"     150/80",
"    </span>",
"    mmHg in treated patients over age 80 and that the efficacy of further reductions in blood pressure need to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Summary of trials of antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials of hypertension in the elderly have consistently demonstrated benefit from antihypertensive therapy, including patients over the age of 80. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapy should be started in elderly hypertensive patients if lifestyle changes are not sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154681926\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of issues need to be considered before initiating antihypertensive drug therapy in the elderly (see",
"    <a class=\"local\" href=\"#H154681933\">",
"     'Problem of orthostatic hypotension'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14493503\">",
"     'Problem of frailty'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower initial doses (approximately one-half that in younger patients) should be used to minimize the risk of side effects.",
"     </li>",
"     <li>",
"      Elderly patients may have sluggish baroreceptor and sympathetic neural responses, as well as impaired cerebral autoregulation. Thus, in the absence of a hypertensive emergency or urgency, blood pressure should be lowered gradually over a period of weeks to months rather than hours to days in order to minimize the risk of ischemic symptoms, particularly in patients with orthostatic hypotension. This approach is consistent with recommendations made by The Seventh Report of the Joint National Committee (JNC 7) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/11\">",
"       11",
"      </a>",
"      ]. Even more caution is advised in the very old, although the benefits from careful therapy probably outweigh the risks in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/21,23\">",
"       21,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The trials showing benefit from the treatment of hypertension in the elderly were performed in relatively fit patients. Greater caution should be applied to frail patients, and treatment may be withheld if orthostatic hypotension is limiting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154681933\">",
"    <span class=\"h3\">",
"     Problem of orthostatic hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential limiting factor to the use of antihypertensive drugs is that orthostatic (postural)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postprandial hypotension are found in as many as 20 percent of elderly patients with isolated systolic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Hypertensive older adults with orthostatic hypotension are significantly more likely to fall than those without orthostatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, antihypertensive treatment in elderly patients is associated with an increased risk of hip fracture during the first one to two months following initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, supine and standing pressures should be measured in elderly patients prior to the initiation of antihypertensive therapy (whether blood pressures are measured in the office or at home). Orthostatic hypotension is diagnosed when, within two to five minutes of quiet standing, one or more of the following is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At least a 20 mmHg fall in systolic blood pressure",
"     </li>",
"     <li>",
"      At least a 10 mmHg fall in diastolic blood pressure",
"     </li>",
"     <li>",
"      Symptoms of cerebral hypoperfusion, such as dizziness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weakness, fatigue, or dizziness following meals may signal post-prandial hypotension, which can be verified by timely measurement of blood pressure. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14493503\">",
"    <span class=\"h3\">",
"     Problem of frailty",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the randomized trials that showed benefit from the treatment of hypertension in older adults included relatively fit patients, since frail patients often have difficulty with participation in such trials. Although there are no trials, older adults who are frail may not benefit from antihypertensive therapy. In an observational study of 2340 adults older than 65 years, the association between blood pressure and mortality was examined according to whether or not individuals were frail (defined as an inability to walk 6 meters in less than 8 seconds) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/48\">",
"     48",
"    </a>",
"    ]. Among frail adults, there was no association between blood pressure and mortality. In addition, a higher blood pressure was associated with a lower risk of death among the most frail (ie, those who could not walk the distance at all). The expected association of a higher blood pressure with a greater mortality risk was observed among the fit individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Choice of antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Heart Association statement on the treatment of blood pressure in ischemic heart disease, the 2007 European Society of",
"    <span class=\"nowrap\">",
"     Hypertension/European",
"    </span>",
"    Society of Cardiology guidelines on the management of hypertension, and meta-analyses from 2008 and 2009 concluded that the amount of blood pressure reduction is the major determinant of reduction in cardiovascular risk in both younger and older patients with hypertension,",
"    <strong>",
"     not",
"    </strong>",
"    the choice of antihypertensive drug [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. When differences in outcomes have been noted, as in the ALLHAT trial, the drug producing better outcomes had better blood pressure control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H3#H3\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Importance of attained blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This general principle of equivalent efficacy in terms of cardiovascular outcomes applies to monotherapy but does",
"    <strong>",
"     not",
"    </strong>",
"    appear to apply to combined antihypertensive therapy. As described below, the combination of an angiotensin inhibitor and a long-acting dihydropyridine calcium channel blocker appears to provide a significant reduction in cardiovascular events at the same attained blood pressure as an angiotensin inhibitor and a thiazide diuretic. (See",
"    <a class=\"local\" href=\"#H154682079\">",
"     'ACCOMPLISH trial of combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     ALLHAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ALLHAT trial of over 41,000 patients with mild hypertension and at least one other risk factor for coronary heart disease found that low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was associated with fewer cardiovascular complications than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/53\">",
"     53",
"    </a>",
"    ]. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    arm was discontinued early because of a higher rate of adverse outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ALLHAT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 57 percent of the patients were greater than 65 years of age. With respect to clinical outcomes at follow-up at nearly five years, the following results were reported in the patients 65 years and older:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of fatal coronary heart disease and nonfatal myocardial infarction (eg, the primary outcome), and all-cause mortality was the",
"      <strong>",
"       same",
"      </strong>",
"      for all three agents.",
"     </li>",
"     <li>",
"      A higher rate of heart failure was observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      , compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      (RR 1.33, 95% CI 1.18-1.49); the relative risk was similar to that in the entire ALLHAT population (",
"      <a class=\"graphic graphic_figure graphicRef62097 \" href=\"UTD.htm?15/52/16206\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      had significantly",
"      <strong>",
"       higher",
"      </strong>",
"      rates of combined cardiovascular disease outcomes (RR 1.13) (",
"      <a class=\"graphic graphic_figure graphicRef52700 \" href=\"UTD.htm?14/60/15310\">",
"       figure 7",
"      </a>",
"      ), combined coronary heart disease (RR 1.11), and heart failure (RR 1.20) (",
"      <a class=\"graphic graphic_figure graphicRef70843 \" href=\"UTD.htm?15/45/16094\">",
"       figure 8",
"      </a>",
"      ). There was also a nonsignificant trend for a higher rate of stroke with lisinopril (RR 1.13, with a 95% CI 0.98-1.30) (",
"      <a class=\"graphic graphic_figure graphicRef50881 \" href=\"UTD.htm?15/34/15918\">",
"       figure 9",
"      </a>",
"      ). Each of these values was similar to those in the entire ALLHAT population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, all three antihypertensive agents were associated with the same cardiovascular and overall mortality and incidence of nonfatal myocardial infarction, a finding consistent with smaller comparative trials in the elderly, such as STOP-Hypertension-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/54\">",
"     54",
"    </a>",
"    ]. The lower rates of some secondary outcomes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    in ALLHAT may have reflected at least in part lower attained blood pressures, rather than a specific drug benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, the superiority of chlorthalidone as compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    in preventing certain secondary endpoints may have been due to the presence a substantial number of black participants; chlorthalidone and lisinopril produced similar results in whites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H4#H4\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'ALLHAT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Long-acting calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-acting calcium channel blockers have proven efficacy and safety in elderly patients with hypertension, particularly those with isolated systolic hypertension. This has been demonstrated in a variety of clinical trials in elderly patients with hypertension, including ALLHAT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/53\">",
"     53",
"    </a>",
"    ], Syst-Eur trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/31\">",
"     31",
"    </a>",
"    ], STOP Hypertension-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/54\">",
"     54",
"    </a>",
"    ], the Syst-China trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/32\">",
"     32",
"    </a>",
"    ], and the ACCOMPLISH trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angiotensin converting enzyme (ACE) inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    had some worse cardiovascular outcomes than low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    in ALLHAT, an effect that may have been due at least in part to greater blood pressure reduction with chlorthalidone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/53\">",
"     53",
"    </a>",
"    ]. In contrast, ACE inhibitors were associated with a lower rate of adverse cardiovascular events than thiazide diuretics at the same degree of blood pressure control in the Second Australian National Blood Pressure (ANBP2) trial of elderly patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/57\">",
"     57",
"    </a>",
"    ]. However, there are potentially important concerns about the design of this trial. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'ALLHAT trial'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H11#H11\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ANBP2 trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many elderly hypertensive patients have a specific indication for an ACE inhibitor or angiotensin II receptor blocker, including heart failure, prior myocardial infarction, and proteinuric chronic kidney disease. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234202072\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that, in the absence of a specific indication for their use (eg, heart failure, myocardial infarction), beta blockers should",
"    <strong>",
"     not",
"    </strong>",
"    be considered for primary therapy of hypertension, particularly in elderly patients. They may be worse than other agents for the prevention of stroke (particularly among smokers) and, perhaps with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H18#H18\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'Beta blockers as initial therapy?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154682079\">",
"    <span class=\"h3\">",
"     ACCOMPLISH trial of combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACCOMPLISH trial evaluated the efficacy of initial combination therapy in 11,506 hypertensive patients (mean age 68, mean blood pressure",
"    <span class=\"nowrap\">",
"     145/80",
"    </span>",
"    mmHg) who were at high risk for cardiovascular events; almost all of whom were being treated with antihypertensive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/56\">",
"     56",
"    </a>",
"    ]. The patients were randomly assigned (without a washout period) to combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    (12.5",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    dose escalation was performed as necessary. The primary end point was achieved significantly less often in the benazepril-amlodipine group (9.6 versus 11.8 percent, hazard ratio 0.80, 95% CI 0.72-0.90). Patients 65 and older as well as 70 and older had the same relative benefit from benazepril-amlodipine as did the overall study population. Office blood pressure control and 24-hour blood pressure measurements were similar in the two groups.",
"   </p>",
"   <p>",
"    The ACCOMPLISH trial is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'ACCOMPLISH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Summary of antihypertensive drug choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the treatment of hypertension with monotherapy, there is agreement from a 2008 meta-analysis and major society guidelines that, in the absence of a specific indication for use of a particular class of antihypertensive drugs (eg, ACE inhibitors and beta blockers for heart failure), it is the attained blood pressure, not the particular drug, that is the primary determinant of outcome with",
"    <strong>",
"     single agent",
"    </strong>",
"    antihypertensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H3#H3\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Importance of attained blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, three classes of drugs are considered first-line therapy for the treatment of hypertension in elderly patients: low-dose thiazide diuretics (eg, 12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ), long-acting calcium channel blockers (most often dihydropyridines), and ACE inhibitors or angiotensin II receptor blockers. A long-acting dihydropyridine or a thiazide diuretic is generally preferred in elderly patients because of increased efficacy in blood pressure lowering.",
"   </p>",
"   <p>",
"    Among elderly patients in whom there is a reasonable likelihood of requiring a second drug (eg, more than",
"    <span class=\"nowrap\">",
"     10/5",
"    </span>",
"    mmHg above goal or failure to attain goal blood pressure with monotherapy), we and many hypertension experts practice according to the results of the ACCOMPLISH trial described above in which there was significant improvement in outcomes at the same attained blood pressure with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/19/16696?source=see_link\">",
"     benazepril",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    compared with benazepril plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H154682079\">",
"     'ACCOMPLISH trial of combination therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We prefer initial therapy with a long-acting dihydropyridine calcium channel blocker. If additional therapy is required, a long-acting ACE",
"    <span class=\"nowrap\">",
"     inhibitor/ARB",
"    </span>",
"    can be added to achieve the desired combination regimen. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Long-acting calcium channel blockers'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to conventional antihypertensive drugs, sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    , which is used to treat angina pectoris, may contribute to blood pressure control in patients with isolated systolic hypertension, preferentially lowering the systolic pressure with few side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In a randomized trial of 40 elderly patients with isolated systolic hypertension, for example, isosorbide dinitrate was associated with a greater reduction in systolic pressure than placebo (27 versus 13 mmHg), with no effect on diastolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/58\">",
"     58",
"    </a>",
"    ]. The fall in blood pressure began within the first week, reached its maximum at four weeks, and persisted to the end of the trial at 12 weeks with no evidence of tachyphylaxis.",
"   </p>",
"   <p>",
"    With all drugs, orthostatic hypotension should be avoided because of the increased risk of falling in older patients. (See",
"    <a class=\"local\" href=\"#H154681933\">",
"     'Problem of orthostatic hypotension'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154681896\">",
"    <span class=\"h2\">",
"     Uncontrolled hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older hypertensive patients are less likely to be controlled than younger antihypertensive patients when treated with antihypertensive drugs. This was best illustrated in a report from the National Health and Nutrition Examination Survey (NHANES) of 13,375 hypertensive adults who had a mean age of 59 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/60\">",
"     60",
"    </a>",
"    ]. Uncontrolled hypertension was defined as a blood pressure",
"    <span class=\"nowrap\">",
"     &ge;140/&ge;90",
"    </span>",
"    mmHg in patients treated with one or two antihypertensive medications.",
"   </p>",
"   <p>",
"    The following findings were noted from 2005 to 2008:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among all patients on one to two antihypertensive medications, the risk of being uncontrolled increased by 28 percent with each 10-year increase in age.",
"     </li>",
"     <li>",
"      Patients who were uncontrolled on one or two antihypertensive drugs were more likely to be older and have a 10-year Framingham CHD risk &gt;20 percent than those who were controlled.",
"     </li>",
"     <li>",
"      These patients accounted for 72 percent of all treated patients with uncontrolled hypertension; the remaining 28 percent had resistant hypertension as defined in the following section. (See",
"      <a class=\"local\" href=\"#H241189091\">",
"       'Resistant hypertension'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    These observations suggest that physicians are reluctant to add a second and third antihypertensive drug in older patients with uncontrolled hypertension, despite their high risk for clinical complications from persistent hypertension. However, older hypertensives are more likely to be frail, to have orthostatic hypotension, and to have lower diastolic blood pressures than younger hypertensive patients, all of which may limit antihypertensive therapy. (See",
"    <a class=\"local\" href=\"#H154681933\">",
"     'Problem of orthostatic hypotension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, while substantial progress can be made, it may not be possible or prudent to fully close the gap between older and younger hypertensive patients in the proportion of treated patients achieving control of hypertension. However, the combination of antihypertensive therapy and lifestyle modifications described above should result in blood pressure control in a greater proportion of older patients. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Lifestyle modifications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H241189091\">",
"    <span class=\"h2\">",
"     Resistant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the same NHANES report as in the preceding section, apparent treatment resistant hypertension was defined as a blood pressure",
"    <span class=\"nowrap\">",
"     &ge;140/&ge;90",
"    </span>",
"    mmHg in patients taking three or more antihypertensive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/60\">",
"     60",
"    </a>",
"    ]. These patients accounted for 28 percent of patients with uncontrolled hypertension in 2005 to 2008, which represented an increase from 16 percent in 1988 to 1994. Clinical characteristics associated with resistant hypertension included older age, obesity, chronic kidney disease, and a Framingham 10-year coronary risk score of more than 20 percent.",
"   </p>",
"   <p>",
"    Issues related to resistant hypertension, including the general approach to therapy, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36728?source=see_link\">",
"     \"Definition, risk factors, and evaluation of resistant hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=see_link\">",
"     \"Treatment of resistant hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     GOAL BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the available evidence, we propose the following blood pressure goals in elderly patients with hypertension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In elderly patients with isolated systolic hypertension, we recommend lowering the systolic pressure to less than 150 mmHg compared with higher values. In such patients, we suggest lowering the systolic pressure to less than 140 mmHg if it can be achieved without producing significant side effects. Elderly patients who are frail or who have orthostatic hypotension are more likely to be unable to obtain a systolic pressure less than 140 mmHg without encountering significant side effects. In patients who cannot achieve either of these systolic blood pressure goals, we suggest a reduction in systolic pressure of at least 20 mmHg.",
"     </li>",
"     <li>",
"      Among patients being treated for isolated systolic hypertension, we suggest that the posttreatment diastolic blood pressure should be greater than 60 mmHg or, in patients with known coronary artery disease, greater than 65 mmHg. A higher diastolic pressure may be required if symptoms that could be attributable to hypoperfusion occur.",
"     </li>",
"     <li>",
"      Among elderly patients with hypertension but",
"      <strong>",
"       not",
"      </strong>",
"      isolated systolic hypertension (ie, patients who have both systolic and diastolic hypertension), we suggest a goal systolic pressure of less than 140 mmHg and a goal diastolic pressure of less than 90 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale for the above approach is presented above, and is further discussed in the ensuing sections. These goals are similar to those in the 2011 American Heart Association consensus document on hypertension in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood pressure reduction should always be gradual in elderly patients and all patients with hypertension should receive nonpharmacologic therapy. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Trials of antihypertensive therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Lifestyle modifications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Isolated systolic hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with hypertension, the systolic pressure goal is less than 140 mmHg, if tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/11\">",
"     11",
"    </a>",
"    ]. As noted above, trials of antihypertensive therapy in patients with isolated systolic hypertension (ie, diastolic pressure less than 90 mmHg) have not evaluated this goal. There is disagreement among experts (including the authors and reviewers of this topic) as to whether the goal in elderly patients with isolated systolic hypertension should be less than 140 mmHg or, as suggested by the authors of HYVET, less than 150 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Trials of antihypertensive therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'HYVET trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These goals may not be easy to achieve, particularly in patients with a baseline systolic pressure greater than 160 mmHg. The achieved systolic pressure in the active treatment group of most every placebo-controlled hypertension trial in the elderly was above 140 mmHg, and, in some cases, the achieved systolic pressure was above 150 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/61\">",
"     61",
"    </a>",
"    ]. However, later trials comparing one drug (or combination) with another achieved lower blood pressures in the elderly. In ACCOMPLISH, for example, the majority of patients were older than 65 years and most had isolated systolic hypertension; the mean achieved blood pressure in this trial was",
"    <span class=\"nowrap\">",
"     132/74",
"    </span>",
"    mmHg, suggesting that the goal blood pressure can be reached in a large number of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'ACCOMPLISH trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the above noted systolic blood pressure goal of less than 140 mmHg (or less than 150 mmHg) is difficult to achieve, the systolic pressure that is reached with two or three antihypertensive agents (even if greater than 140 mmHg) may be a reasonable interim goal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, the goal in the SHEP trial was a systolic pressure at least 20 mmHg below the baseline level if the initial value was between 160 and 180 mmHg, or below 160 mmHg if the initial value was above 180 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential limitation to the above goals is that lowering the blood pressure may impair mental function, leading to manifestations such as confusion or sleepiness. In such patients, antihypertensive therapy should be reduced and the systolic pressure allowed to rise to a level at which these symptoms resolve.",
"   </p>",
"   <p>",
"    Another concern when treating elderly patients with isolated systolic hypertension is that the low diastolic pressure after therapy may impair tissue perfusion (particularly coronary perfusion) and possibly increase cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/8,16,20,21\">",
"     8,16,20,21",
"    </a>",
"    ]. However, as noted above, lower diastolic blood pressures are associated with worse outcomes (both cardiovascular and noncardiovascular) in both treated and untreated patients (",
"    <a class=\"graphic graphic_figure graphicRef73430 \" href=\"UTD.htm?18/38/19055\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/27\">",
"     27",
"    </a>",
"    ]. These findings suggest that the worse outcomes are probably explained by poor health associated with lower blood pressures, not an adverse effect of antihypertensive therapy. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Importance of diastolic pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite these observations, there may be a threshold diastolic blood pressure below which adverse cardiovascular outcomes might increase in elderly patients. When treating patients with isolated systolic hypertension, we and others (including JNC 7) suggest a",
"    <strong>",
"     minimum posttreatment diastolic pressure of 60 mmHg overall or perhaps 65 mmHg in patients with known coronary artery disease",
"    </strong>",
"    unless symptoms that could be attributable to hypoperfusion occur at higher pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/11,24,26\">",
"     11,24,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Mild isolated systolic hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding data reflect observations from the major randomized trials in elderly patients in which the baseline systolic pressure for study entry was 160 mmHg or higher. There have been",
"    <strong>",
"     no",
"    </strong>",
"    randomized trials in patients with mild isolated systolic hypertension who have systolic pressures between 140 and 159 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Systolic and diastolic hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual goal blood pressure is less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in average risk patients with systolic and diastolic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/27/25018/abstract/11\">",
"     11",
"    </a>",
"    ]. There is evidence supporting a lower goal blood pressure in patients with atherosclerotic cardiovascular disease, diabetes mellitus, or chronic kidney disease. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of hypertension among elderly subjects (age greater than 60 to 65 years) is reportedly as high as 60 to 80 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated systolic hypertension (ISH), which is common in the elderly, has been generally defined as a systolic blood pressure equal to or above 160 mmHg, with a diastolic blood pressure below 90 mmHg (stage 2 ISH). However, a systolic pressure of 140 mmHg is the upper limit of normal at all ages (ie, a blood pressure",
"      <span class=\"nowrap\">",
"       140&ndash;159/&lt;90",
"      </span>",
"      mmHg is stage 1 ISH). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Isolated systolic hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elderly hypertensive patients should attempt lifestyle modification to lower the blood pressure. If goal blood pressure is not attained with lifestyle modification, antihypertensive therapy should be initiated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Lifestyle modifications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of a hypertensive emergency or urgency, blood pressure reduction should always be gradual in elderly patients. All patients should receive nonpharmacologic therapy, particularly dietary salt restriction and weight loss in obese patients. Drug therapy should be started if lifestyle changes are not sufficient. A potential limiting factor to the use of antihypertensive drugs is that orthostatic (postural)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      postprandial hypotension is common among elderly hypertensive patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Lifestyle modifications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among elderly hypertensive patients who require antihypertensive medication and who do not have an indication for a specific drug, we recommend initial monotherapy with a low dose thiazide-type diuretic, an angiotensin converting enzyme (ACE)",
"      <span class=\"nowrap\">",
"       inhibitor/angiotensin",
"      </span>",
"      II receptor blocker (ARBs), or a long-acting calcium channel blocker (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Among elderly patients in whom there is a reasonable likelihood of requiring a second drug (eg, systolic pressure more than",
"      <span class=\"nowrap\">",
"       10/5",
"      </span>",
"      mmHg above goal), we suggest initial therapy with a long-acting dihydropyridine calcium channel blocker (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is because, if additional therapy is required, a long-acting ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      can be added to achieve the desired combination regimen of a long-acting ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB",
"      </span>",
"      plus a long-acting dihydropyridine calcium channel blocker. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Summary of antihypertensive drug choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In elderly patients with isolated systolic hypertension, we recommend lowering the systolic pressure to less than 150 mmHg compared with higher values (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In such patients, we suggest lowering the systolic pressure to less than 140 mmHg compared with higher values if it can be achieved without producing significant side effects (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Elderly patients who are frail or who have orthostatic hypotension are more likely to be unable to obtain a systolic pressure less than 140 mmHg without encountering significant side effects. In patients with isolated systolic hypertension who cannot achieve either of these systolic blood pressure goals, we suggest a reduction in systolic pressure of at least 20 mmHg (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Goal blood pressure'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Among patients being treated for isolated systolic hypertension, we suggest that the posttreatment diastolic blood pressure should be greater than 60 mmHg overall or, in patients with known coronary artery disease, greater than 65 mmHg (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Higher diastolic pressures may be required if symptoms occur that could be attributable to hypoperfusion. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Goal blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among elderly patients with hypertension but",
"      <strong>",
"       not",
"      </strong>",
"      isolated systolic hypertension (ie, those with combined systolic and diastolic hypertension), we suggest a goal systolic pressure of less than 140 mmHg and a goal diastolic pressure of less than 90 mmHg (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Goal blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is evidence supporting a lower goal blood pressure in patients with atherosclerotic cardiovascular disease, diabetes mellitus, or chronic kidney disease. The supportive data are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A potential limitation to the above blood pressure goals is that lowering the blood pressure may impair mental function, leading to manifestations such as confusion, lethargy or sleepiness. In such patients, antihypertensive therapy should be reduced and the systolic pressure allowed to rise to a level at which these symptoms resolve. If the symptoms developing in the setting of rapid blood pressure reduction, a subsequent effort to reduce the blood pressure more gradually should be attempted.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/1\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/2\">",
"      Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/3\">",
"      Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/4\">",
"      Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/5\">",
"      Vasan RS, Larson MG, Leip EP, et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/6\">",
"      Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/7\">",
"      Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/8\">",
"      Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/9\">",
"      National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group. Hypertension 1994; 23:275.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (NICE clinical guideline update). Available at: file://www.nice.org.uk. Accessed January 21, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/11\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/12\">",
"      Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension 2000; 35:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/13\">",
"      Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/14\">",
"      Franklin SS, Gustin W 4th, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/15\">",
"      Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/16\">",
"      Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001; 103:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/17\">",
"      Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med 2007; 357:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/18\">",
"      Young JH, Klag MJ, Muntner P, et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002; 13:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/19\">",
"      Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/20\">",
"      Pastor-Barriuso R, Banegas JR, Dami&aacute;n J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/21\">",
"      Protogerou AD, Safar ME, Iaria P, et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 2007; 50:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/22\">",
"      Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/23\">",
"      Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/24\">",
"      Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/25\">",
"      Vok&oacute; Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999; 34:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/26\">",
"      Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/27\">",
"      Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002; 136:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/28\">",
"      Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/29\">",
"      Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/30\">",
"      Staessen JA, Richart T, Verdecchia P. Reducing blood pressure in people of different ages. BMJ 2008; 336:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/31\">",
"      Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/32\">",
"      Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/33\">",
"      Staessen JA, Richart T, Birkenh&auml;ger WH. Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension 2007; 49:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/34\">",
"      Chaudhry SI, Krumholz HM, Foody JM. Systolic hypertension in older persons. JAMA 2004; 292:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/35\">",
"      Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997; 278:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/36\">",
"      Ofili EO, Cohen JD, St Vrain JA, et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA 1998; 279:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/37\">",
"      Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/38\">",
"      Staessen JA, Fagard R, Thijs L, et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/39\">",
"      Tuomilehto J, Rastenyte D, Birkenh&auml;ger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/40\">",
"      Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/41\">",
"      Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/42\">",
"      Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/43\">",
"      Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/44\">",
"      Vanhanen H, Thijs L, Birkenh&auml;ger W, et al. Associations of orthostatic blood pressure fall in older patients with isolated systolic hypertension. Syst-Eur Investigators. J Hypertens 1996; 14:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/45\">",
"      Applegate WB, Davis BR, Black HR, et al. Prevalence of postural hypotension at baseline in the Systolic Hypertension in the Elderly Program (SHEP) cohort. J Am Geriatr Soc 1991; 39:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/46\">",
"      Gangavati A, Hajjar I, Quach L, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc 2011; 59:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/47\">",
"      Butt DA, Mamdani M, Austin PC, et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med 2012; 172:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/48\">",
"      Odden MC, Peralta CA, Haan MN, Covinsky KE. Rethinking the association of high blood pressure with mortality in elderly adults: the impact of frailty. Arch Intern Med 2012; 172:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/49\">",
"      Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/50\">",
"      Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/51\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/52\">",
"      Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/53\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/54\">",
"      Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/55\">",
"      Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/56\">",
"      Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/57\">",
"      Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/58\">",
"      Duchier J, Iannascoli F, Safar M. Antihypertensive effect of sustained-release isosorbide dinitrate for isolated systolic systemic hypertension in the elderly. Am J Cardiol 1987; 60:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/59\">",
"      Starmans-Kool MJ, Kleinjans HA, Lustermans FA, et al. Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule. J Hum Hypertens 1998; 12:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/60\">",
"      Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/27/25018/abstract/61\">",
"      Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3863 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25018=[""].join("\n");
var outline_f24_27_25018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H149558066\">",
"      HYPERTENSION AWARENESS AND CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISOLATED SYSTOLIC HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Importance of diastolic pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lifestyle modifications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - TONE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trials of antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - SHEP trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Syst-Eur trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - MRC trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - HYVET trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Summary of trials of antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154681926\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154681933\">",
"      - Problem of orthostatic hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14493503\">",
"      - Problem of frailty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choice of antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - ALLHAT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Long-acting calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H234202072\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H154682079\">",
"      - ACCOMPLISH trial of combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Summary of antihypertensive drug choice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154681896\">",
"      Uncontrolled hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H241189091\">",
"      Resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      GOAL BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Mild isolated systolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Systolic and diastolic hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3863|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/12/17614\" title=\"figure 1A\">",
"      Prevalence of HTN in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/46/19182\" title=\"figure 1B\">",
"      Prevalence of HTN in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/58/35759\" title=\"figure 2\">",
"      J curve systolic HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/38/19055\" title=\"figure 3\">",
"      J curve diastolic HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/23/33142\" title=\"figure 4A\">",
"      Mortality HTN over 65 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/44/21188\" title=\"figure 4B\">",
"      CV mortality HTN over 65 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/24/20877\" title=\"figure 5\">",
"      Treatment of systolic HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/52/16206\" title=\"figure 6\">",
"      RR of HF amlo vs chlor ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/60/15310\" title=\"figure 7\">",
"      RR of CV lisin vs chlor ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/45/16094\" title=\"figure 8\">",
"      RR of HF lisin vs chlor ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/34/15918\" title=\"figure 9\">",
"      RR stroke lisin vs chlor ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/23/7548\" title=\"table 1\">",
"      Effects of antihypertensive treatment in the elderly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36728?source=related_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26823?source=related_link\">",
"      Increased pulse pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23828?source=related_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4755?source=related_link\">",
"      The prevalence and control of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=related_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_27_25019="Frequency fetal arrhythmias";
var content_f24_27_25019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Type and distribution of arrythmias in 1384 fetuses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature atrial contractions",
"       </td>",
"       <td>",
"        1213",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supraventricular tachycardia",
"       </td>",
"       <td>",
"        69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete heart block",
"       </td>",
"       <td>",
"        39",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial flutter",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2nd degree AV block",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinus tachycardia",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular tachycardia",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Junctional tachycardia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinus bradycardia",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Kleinman, CS, Nehgme, R, Copel, JA. Maternal-Fetal Medicine, Principles and Practice, 5th edition, Saunders, 2004, p 466.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25019=[""].join("\n");
var outline_f24_27_25019=null;
var title_f24_27_25020="Physical signs in miliary TB";
var content_f24_27_25020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical signs in patients with miliary tuberculosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sign",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maartens, 1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kim, 1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gelb, 1973",
"       </td>",
"       <td class=\"subtitle1\">",
"        Munt, 1971",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proudfoot, 1969",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        96*",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        82",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary (rales, rhonchi, rubs,&nbsp;signs of effusion)",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatomegaly",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenomegaly",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic (altered mental status, meningismus)",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatologic",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive PPD",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All numbers are percentages.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25020=[""].join("\n");
var outline_f24_27_25020=null;
var title_f24_27_25021="mSWAT";
var content_f24_27_25021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Severity Weighted Assessment Tool for Mycosis Fungoides and Sezary Syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Body region",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Percent BSA in body region",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Assessment of involvement in patient's skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Patch*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Plaque",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        Tumor",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anterior trunk",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arms",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forearms",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hands",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior trunk",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buttocks",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thighs",
"       </td>",
"       <td class=\"centered\">",
"        19",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Legs",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feet",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Groin",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td align=\"right\" class=\"sublist1_start\">",
"        <strong>",
"         Subtotal of lesion BSA:",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td align=\"right\" class=\"sublist1\">",
"        Weighting factor:",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        x1",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        x2",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        x4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"right\">",
"        <strong>",
"         Subtotal lesion BSA x weighting factor:",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Modified Severity Weighted Assessment Tool score equals summation of each column line.",
"    <div class=\"footnotes\">",
"     BSA: body surface area; mSWAT: modified Severity Weighted Assessment Tool.",
"     <br/>",
"     * Any size lesion without induration or significant elevation above the surrounding uninvolved skin; poikiloderma may be present.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Any size lesion that is elevated or indurated; crusting, ulceration, or poikiloderma may be present.",
"     <br/>",
"     &Delta; Any solid or nodular lesion &ge;1 cm in diameter with evidence of deep infiltration in the skin and/or vertical growth.",
"    </div>",
"    <div class=\"reference\">",
"     From: Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol; 29(18), 2011:2598-2607. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25021=[""].join("\n");
var outline_f24_27_25021=null;
var title_f24_27_25022="Case studies of FUO I";
var content_f24_27_25022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54701%7EID%2F66395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54701%7EID%2F66395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Case studies of fever of unknown origin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Author",
"       </td>",
"       <td>",
"        Alt",
"       </td>",
"       <td>",
"        Petersdorf",
"       </td>",
"       <td>",
"        Vanderschueren",
"       </td>",
"       <td>",
"        Miller",
"       </td>",
"       <td>",
"        Knockaert",
"       </td>",
"       <td>",
"        Bleeker-Rovers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Year",
"       </td>",
"       <td>",
"        1913-30",
"       </td>",
"       <td>",
"        1952-59",
"       </td>",
"       <td>",
"        1990-99",
"       </td>",
"       <td>",
"        1989-93",
"       </td>",
"       <td>",
"        1980-89",
"       </td>",
"       <td>",
"        2003-2005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Locale",
"       </td>",
"       <td>",
"        Boston",
"       </td>",
"       <td>",
"        Seattle",
"       </td>",
"       <td>",
"        Belgium",
"       </td>",
"       <td>",
"        London",
"       </td>",
"       <td>",
"        Belgium",
"       </td>",
"       <td>",
"        Netherlands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Subpopulation",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"       <td>",
"        AIDS",
"       </td>",
"       <td>",
"        Elderly",
"       </td>",
"       <td>",
"        Adults&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Case",
"definition*",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Number",
"of cases",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"7\" rowspan=\"1\">",
"        Diagnostic categories&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasms",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multisystem&bull;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"diagnosis",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 1: no diagnosis at time of hospital discharge; 2: temp &gt;101&deg;F (38.3 &deg;C), duration &gt;3 weeks, undiagnosed &gt;1 week; 3 = temp &gt;101.3&deg;F (38.5&deg;C), duration &gt;2 weeks, undiagnosed.",
"     <br>",
"      &bull; Includes collagen vascular disorders (eg, systemic lupus erythematosus, rheumatoid arthritis, and vasculitis), and granulomatous diseases (eg, sarcoidosis).",
"      <br>",
"       &Delta; Numbers represent percentages.",
"       <br>",
"        &loz; Immunocompromised excluded.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Alt, H, et al. JAMA 1930; 94:1457. Petersdorf, RG, et al. Medicine (Baltimore) 1961; 40:1. Vanderschueren, S, et al. Arch Intern Med 2003; 163:1033. Miller, RF, et al. Int J STD AIDS 1996; 7:170. Knockaert, DC, et al. Clin Infect Dis 1994; 18:601. Bleeker-Rovers, CP, et al. Medicine (Baltimore) 2007; 86:26.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Case studies of fever of unknown origin: prevalent diagnoses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Case study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Alt",
"        </p>",
"        <p>",
"         1913-30",
"        </p>",
"        <p>",
"         n = 23",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Petersdorf",
"        </p>",
"        <p>",
"         1952-59",
"        </p>",
"        <p>",
"         n = 93",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         de Kleijn",
"        </p>",
"        <p>",
"         1992-94",
"        </p>",
"        <p>",
"         n = 117",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Vanderschueren",
"        </p>",
"        <p>",
"         1990-99",
"        </p>",
"        <p>",
"         n = 192",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Miller",
"        </p>",
"        <p>",
"         1989-93",
"        </p>",
"        <p>",
"         n = 72",
"        </p>",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Knockaert",
"        </p>",
"        <p>",
"         1980-89",
"        </p>",
"        <p>",
"         n = 41",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatic fever",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal abscess",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocarditis",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterial",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solid tumor",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoid",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupus",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant cell arteritis",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug fever",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factitious fever",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Numbers represent number of cases.",
"    </div>",
"    <div class=\"reference\">",
"     Alt, H, et al. JAMA 1930; 94:1457. Petersdorf, RG. Arch Intern Med 1992; 152:21. de Kleijn, EM, et al. Medicine (Baltimore) 1997; 76:392. Vanderschueren, S, et al. Arch Intern Med 2003; 163:1033. Miller, RF, et al. Int J STD AIDS 1996; 7:170. Knockaert, DC, et al. Clin Infect Dis 1994; 18:601.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25022=[""].join("\n");
var outline_f24_27_25022=null;
var title_f24_27_25023="Retroperitoneoscopic bilateral adrenalectomy position";
var content_f24_27_25023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Retroperitoneoscopic bilateral adrenalectomy position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the patient in the prone position and endoscopic instrument placement for performing a retroperitoneoscopic bilateral adrenalectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_27_25023=[""].join("\n");
var outline_f24_27_25023=null;
